10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended May 31, 2018

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission File Number 333-127953

SOLARWINDOW TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Nevada	59-3509694
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
10632 Little Patuxent Parkway, Suite 406 Columbia, Maryland	21044
(Address of principal executive offices)	(Zip Code)

(800) 213-0689

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting company	x
(Do not check if a smaller reporting company)		Emerging growth company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in 12b-2 of the Exchange Act). Yes o No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 36,292,656 shares of common stock, par value $0.001, were outstanding on July 12, 2018.

SOLARWINDOW TECHNOLOGIES, INC.

FORM 10-Q

For the Quarterly Period Ended May 31, 2018

Table of Contents

PART I FINANCIAL INFORMATION
Item 1.	Consolidated Financial Statements (Unaudited)	3
	Consolidated Balance Sheets	3
	Consolidated Statements of Operations	4
	Consolidated Statements of Stockholders’ Equity (Deficit)	5
	Consolidated Statements of Cash Flows	6
	Notes to Consolidated Financial Statements	7
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	16
Item 4.	Controls and Procedures	23
PART II OTHER INFORMATION
Item 6.	Exhibits	24
Signatures		25
Certifications

2

PART I — FINANCIAL INFORMATION 

Item 1. Consolidated Financial Statements (Unaudited)

SOLARWINDOW TECHNOLOGIES, INC.
CONSOLIDATED BALANCE SHEETS
	May 31,			August 31,
	2018			2017
	(Unaudited)
ASSETS
Current assets
Cash and cash equivalents	$	1,191,587		$	670,853
Deferred research and development costs		134,139			91,204
Prepaid expenses and other current assets		44,764			16,698
Total current assets		1,370,490			778,755
Equipment, net of accumulated depreciation of $65,049 and $53,181, respectively		43,665			52,953
Total assets	$	1,414,155		$	831,708
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities
Accounts payable and accrued expenses	$	88,683		$	230,184
Total current liabilities		88,683			230,184
Bridge note payable to related party		600,000			600,000
Convertible promissory note payable to related party, net of discount of $789,340 and $413,377, respectively		2,210,660			2,586,623
Interest payable to related party		1,391,830			1,046,377
Total long term liabilities		4,202,490			4,233,000
Total liabilities		4,291,173			4,463,184
Commitments and contingencies
Stockholders' equity (deficit)
Preferred stock: $0.10 par value; 1,000,000 shares authorized, no shares issued and outstanding		-			-
Common stock: $0.001 par value; 300,000,000 shares authorized, 36,292,656 and 34,329,691 shares issued and outstanding at May 31, 2018 and August 31, 2017, respectively		36,293			34,330
Additional paid-in capital		41,749,952			35,363,946
Retained deficit		(44,663,263	)		(39,029,752	)
Total stockholders' equity (deficit)		(2,877,018	)		(3,631,476	)
Total liabilities and stockholders' equity (deficit)	$	1,414,155		$	831,708
(The accompanying notes are an integral part of these consolidated financial statements)

3

SOLARWINDOW TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
FOR THE THREE AND NINE MONTHS ENDED MAY 31, 2018 AND 2017
	Three Months Ended May 31,						Nine Months Ended May 31,
	2018			2017			2018			2017
Revenue	$	-		$	-		$	-		$	-
Operating expense
Selling, general and administrative		601,782			516,657			3,058,476			2,167,722
Research and product development		588,986			294,791			1,531,280			812,072
Total operating expense		1,190,768			811,448			4,589,756			2,979,794
Loss from operations		(1,190,768	)		(811,448	)		(4,589,756	)		(2,979,794	)
Other income (expense)
Interest expense		(128,706	)		(79,162	)		(345,453	)		(231,626	)
Accretion of debt discount		(125,422	)		(311,727	)		(698,302	)		(999,718	)
Total other income (expense)		(254,128	)		(390,889	)		(1,043,755	)		(1,231,344	)
Net loss	$	(1,444,896	)	$	(1,202,337	)	$	(5,633,511	)	$	(4,211,138	)
Basic and Diluted Loss per Common Share	$	(0.04	)	$	(0.04	)	$	(0.16	)	$	(0.14	)
Weighted average number of common shares outstanding - basic and diluted		36,270,592			33,810,348			35,924,340			30,347,594
(The accompanying notes are an integral part of these consolidated financial statements)

4

SOLARWINDOW TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)
FOR THE NINE MONTHS ENDED MAY 31, 2018 AND THE YEAR ENDED AUGUST 31, 2017
					Additional						Total
	Common Stock				Paid-in			Retained			Stockholders'
	Shares		Amount		Capital			Deficit			Equity (Deficit)
Balance, August 31, 2016		28,500,221	$	28,500	$	33,729,715		$	(33,676,327	)	$	81,888
July 2017 Private Placement units issued		300,000		300		689,700			-			690,000
Stock based compensation related to stock issuances		138,904		139		448,463			-			448,602
Exercise of warrants for cash		129,000		129		301,731			-			301,860
Exercise of warrants on a cashless basis		5,215,046		5,215		(5,215	)		-			-
Exercise of stock options on a cashless basis		46,520		47		(47	)		-			-
Stock based compensation due to common stock purchase options		-		-		199,599			-			199,599
Net loss for the year ended August 31, 2017		-		-		-			(5,353,425	)		(5,353,425	)
Balance, August 31, 2017		34,329,691		34,330		35,363,946			(39,029,752	)		(3,631,476	)
September 2017 Private Placement units issued		821,600		822		2,554,354			-			2,555,176
Stock based compensation related to stock issuances		210,000		210		1,022,490			-			1,022,700
Exercise of warrants for cash		119,500		120		394,030			-			394,150
Exercise of warrants on a cashless basis		665,703		665		(665	)		-			-
Exercise of stock options on a cashless basis		146,162		146		(146	)		-			-
Stock based compensation due to common stock purchase options		-		-		1,341,678			-			1,341,678
Discount on convertible promissory note due warrant modifications		-		-		1,074,265			-			1,074,265
Net loss for the Nine months ended May 31, 2018		-		-		-			(5,633,511	)		(5,633,511	)
Balance, May 31, 2018		36,292,656	$	36,293	$	41,749,952		$	(44,663,263	)	$	(2,877,018	)
(The accompanying notes are an integral part of these consolidated financial statements)

5

SOLARWINDOW TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
FOR THE NINE MONTHS ENDED MAY 31, 2018 AND 2017
	Nine Months Ended May 31,
	2018			2017
Cash flows from operating activities
Net loss	$	(5,633,511	)	$	(4,211,138	)
Adjustments to reconcile net loss to net cash flows from operating activities
Depreciation		11,869			9,835
Stock based compensation expense		2,364,378			565,124
Accretion of debt discount		698,302			999,718
Changes in operating assets and liabilities:
Decrease (increase) in deferred research and development costs		(42,935	)		258,807
Decrease (increase) in prepaid expenses and other current assets		(28,066	)		(32,606	)
Increase (decrease) in accounts payable and accrued expenses		(141,501	)		5,439
Increase (decrease) in interest payable		345,453			230,174
Net cash flows from operating activities		(2,426,011	)		(2,174,647	)
Cash flows from investing activity
Purchase of equipment		(2,581	)		(45,547	)
Net cash flows from investing activity		(2,581	)		(45,547	)
Cash flows from financing activities
Proceeds from the issuance of equity securities		2,949,326			-
Repayment of promissory note		-			(18,146	)
Net cash flows from financing activities		2,949,326			(18,146	)
Change in cash and cash equivalents		520,734			(2,238,340	)
Cash and cash equivalents at beginning of period		670,853			2,509,215
Cash and cash equivalents at end of period	$	1,191,587		$	270,875
Supplemental disclosure of cash flow information:
Interest paid in cash	$	-		$	1,453
Income taxes paid in cash	$	-		$	-
Supplemental disclosure of non-cash transactions:
Discount on convertible promissory note due to to warrant modifications	$	1,074,265		$	-
(The accompanying notes are an integral part of these consolidated financial statements)

6

SOLARWINDOW TECHNOLOGIES, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – Basis of Presentation, Organization, Recent Accounting Pronouncements and Going Concern

Basis of Presentation

The unaudited financial statements of SolarWindow Technologies, Inc. (the “Company”) as of May 31, 2018, and for the three and nine months ended May 31, 2018 and 2017, have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for interim financial reporting and include the Company’s wholly-owned subsidiaries, Kinetic Energy Corporation (“KEC”), and New Energy Solar Corporation (“New Energy Solar”). Accordingly, they do not include all of the disclosures required by accounting principles generally accepted in the United States for complete financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended August 31, 2017, as filed with the Securities and Exchange Commission as part of the Company’s Form 10-K. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the interim financial information have been included. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.

Organization

SolarWindow Technologies, Inc. was incorporated in the State of Nevada on May 5, 1998, under the name “Octillion Corp.” On December 2, 2008, the Company amended its Articles of Incorporation to effect a change of name to New Energy Technologies, Inc. Effective as of March 9, 2015, the Company amended its Articles of Incorporation to change its name to SolarWindow Technologies, Inc. to align the company name with its brand identity. The Company’s ticker symbol changed to WNDW.

Until the fourth quarter of the 2015 fiscal year, the Company was developing two sustainable electricity generating systems. These novel technologies are branded as SolarWindow™ and MotionPower™. On March 2, 2015, the Company announced its exclusive focus on SolarWindow™.

The Company’s SolarWindow™ technology harvests light energy from the sun and artificial sources to generate electricity from a transparent coating of organic photovoltaic solar cells applied to glass or plastics, creating a “photovoltaic” effect. Photovoltaics are best known as “solar panels” providing a method to generate electricity using solar cells to convert energy from the sun into a flow of electrons. Conventional PV power is generated by solar modules composed of interconnected mono- or poly-crystalline cells containing PV and electricity-conducting materials. These materials are usually opaque (i.e., not see-through) and only effectively generate electricity with sun light. The Company’s researchers have replaced these materials with a very thin layer of specially developed compounds that allow our SolarWindow™ technology to remain see-through or “transparent,” while generating electricity when exposed to either sun or artificial light.

7

Recent Accounting Pronouncements

In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a free-standing equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. Management is currently assessing the impact the adoption of ASU 2017-11 will have on the Company’s Consolidated Financial Statements.

In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting. The amendments in this Update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for public business entities for reporting periods for which financial statements have not yet been issued. Management is currently assessing the impact the adoption of ASU 2017-09 will have on the Company’s Consolidated Financial Statements.

In March 2016, the FASB issued ASU No. 2016-09, “Compensation-Stock Compensation: Improvements to Employee Share-Based Payment Accounting (Topic 718)”, which is intended to simplify several aspects of the accounting for share-based payment award transactions. The guidance is effective for our current fiscal year. The adoption of ASU 2016-09 did not have a material impact on the Consolidated Financial Statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842)”, which supersedes ASC Topic 840, Leases, and creates a new topic, ASC 842, Leases. The new guidance requires the recognition of lease assets and liabilities for operating leases with terms of more than 12 months. Presentation of leases within the consolidated statements of operations and consolidated statements of cash flows will be generally consistent with the current lease accounting guidance. The ASU is effective for reporting periods beginning after December 15, 2018, with early adoption permitted. The Company does not expect this accounting update to have a material effect on its Consolidated Financial Statements.

In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”). The standard requires that deferred tax assets and liabilities be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. ASU 2015-17 is effective for our current fiscal year. The adoption of ASU 2015-17 did not have a material impact on the Consolidated Financial Statements.

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”, to clarify the principles used to recognize revenue for all entities. In March 2016, the FASB issued ASU 2016-08 to further clarify the implementation guidance on principal versus agent considerations. The guidance is effective for annual and interim periods beginning after December 15, 2017. The Company does not expect this accounting update to have a material effect on its Consolidated Financial Statements.

The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion. The Company believes that none of the new standards will have a significant impact on its Consolidated Financial Statements.

8

Going Concern

The Company does not have any commercialized products, has not generated any revenue since inception and has sustained recurring losses and negative cash flows from operations since inception. Due to the “start-up” nature of our business, we expect to incur losses as we continue development of our products and technologies. As of May 31, 2018, the Company has incurred recurring operating losses since inception of $44,663,263. As of May 31, 2018, the Company had approximately $1,191,587 of cash on hand and current liabilities of $88,683. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which contemplates continuation of the Company as a going concern, which is dependent upon the Company’s ability to establish itself as a profitable business.

As of the date of filing of the Company’s most recent Form 10-K on November 22, 2017, based on management’s assessment, the Company had sufficient cash to meet its funding requirements for the next twelve months. However, currently, based upon the Company’s near term anticipated level of operations and expenditures, management believes that cash on hand should be sufficient to enable the Company to continue operations through January 2019 or approximately six months from the date of this quarterly report. In view of these conditions, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. These consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements.

The Company has negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The Company expects that it will need to continue to raise substantial additional capital to accomplish its business plan over the next several years, in line with previous expectations. The Company will seek additional funding through private equity or convertible debt. If adequate funds are not available on reasonable terms, or at all, it would result in a material adverse effect on the Company’s business, operating results, financial condition and prospects. In particular, the Company may be required to delay; reduce the scope of or terminate its research and development programs; sell rights to its SolarWindow™ technology and/or MotionPower™ technology, or other technologies or products based upon these technologies; or license the rights to these technologies or products on terms that are less favorable to the Company than might otherwise be available.

NOTE 2 - Debt

As of May 31, 2018 and August 31, 2017, the Company had the following outstanding debt balances:

	Issue	Maturity			Debt					Interest
	Date	Date	Principal		Discount			Balance		Payable
As of May 31, 2018:
March 2015 Loan as amended	3/4/2015	12/31/2019	$	600,000	$	-		$	600,000	$	166,510
2013 Note as amended	10/7/2013	12/31/2019		3,000,000		(789,340	)		2,210,660		1,225,320
			$	3,600,000	$	(789,340	)	$	2,810,660	$	1,391,830
As of August 31, 2017:
March 2015 Loan as amended	3/4/2015	12/31/2017	$	600,000	$	-		$	600,000	$	113,465
2013 Note as amended	10/7/2013	12/31/2017		3,000,000		(413,377	)		2,586,623		932,912
			$	3,600,000	$	(413,377	)	$	3,186,623	$	1,046,377

March 2015 Loan as Amended

On March 4, 2015, the Company entered into a Bridge Loan Agreement with 1420468 Alberta Ltd. (which has since been merged with and into Kalen Capital Corporation, a British Columbia corporation wholly-owned by our Chairman, Harmel S. Rayat (the “Investor”)). Pursuant the Bridge Loan Agreement, the Company borrowed $600,000 at an annual interest rate of 7% (the “March 2015 Loan”), compounded quarterly, with a default rate of 15%.

On November 3, 2017, the Company entered into the Third Amendment related to the March 2015 Loan pursuant to which the Company and the Investor amended the March 2015 loan to extend the maturity date to December 31, 2019. As consideration for the note extension, the interest rate was increased to 10.5%.

9

During the three months ended May 31, 2018 and 2017, the Company recognized $19,763 and $12,156, respectively, of interest expense. During the nine months ended May 31, 2018 and 2017, the Company recognized $53,045 and $35,462, respectively, of interest expense. During the three and nine months ended May 31, 2018, the Company recognized no debt discount accretion. During the three and nine months ended May 31, 2017, the Company recognized debt discount accretion of $0 and $74,702, respectively.

2013 Note as Amended

On October 7, 2013, the Company sold to the Investor an unsecured Convertible Promissory Note (the “2013 Note”) in the amount of $3,000,000 with 7% interest compounded quarterly. According to the terms of the amended 2013 Note, the Investor may elect to convert principal and accrued interest into units of the Company’s equity securities, with each Unit consisting of (a) one share of common stock; and (b) one Stock Purchase Warrant for the purchase of one share of common stock. The conversion price for each Unit is the lesser of (i) $1.37; or (ii) 70% of the 20 day average closing price of the Company’s common stock prior to conversion, subject to a floor of $1.00 with the exercise price of each Warrant being equal to 60% of the 20 day average closing price of the Company’s common stock prior to conversion. If issued, the Warrant included in the Units will be exercisable for a period of five years. As of May 31, 2018, if the investor elected to convert the entirety of amounts owing under the 2013 Note, the Company would be obligated to issue a warrant for the purchase of 3,084,175 shares of common stock.

On November 3, 2017, the Company entered into the Third Amendment related to the 2013 Note pursuant to which the Company and the Investor amended the 2013 Note to extend the maturity date to December 31, 2019. As consideration for the note extension, the interest rate was increased to 10.5% and all outstanding warrants held by the Investor had their maturity date extended to December 31, 2022, as described below, resulting in an additional debt discount of $1,074,265 as of November 3, 2017. The modification did not result in a gain or loss due to the related party nature of the transaction.

The maturity date of the remaining Series M Warrant to purchase 246,000 shares of common stock was extended from December 31, 2020 to December 31, 2022. The Company recorded $82,656 as a debt discount to recognize the increase in value for the extension of the expiration date.

The maturity date of the Series N Warrant to purchase 767,000 shares of common stock was extended from December 31, 2020 to December 31, 2022. The Company recorded $327,509 as a debt discount to recognize the increase in value for the extension of the expiration date.

The maturity date of the Series P Warrant to purchase 213,500 shares of common stock was extended from April 30, 2018 to December 31, 2022. The Company recorded $348,219 as a debt discount to recognize the increase in value for the extension of the expiration date.

The maturity date of the Series R Warrant to purchase 468,750 shares of common stock was extended from June 20, 2021 to December 31, 2022. The Company recorded $295,781 as a debt discount to recognize the increase in value for the extension of the expiration date.

The maturity date of the Series S-A Warrant to purchase 300,000 shares of common stock was extended from July 24, 2022 to December 31, 2022. The Company recorded $20,100 as a debt discount to recognize the increase in value for the extension of the expiration date.

Interest expense related to the 2013 Note, as amended, amounted to $108,943 and $67,006 during the three months ended May 31, 2018 and 2017, respectively. Interest expense amounted to $292,408 and $195,480 during the nine months ended May 31, 2018 and 2017, respectively.

10

Accretion of the debt discount related to the 2013 Note as amended amounted to $125,422 and $311,727 during the three months ended May 31, 2018 and 2017, respectively and $698,302 and $925,016 during the nine months ended May 31, 2018 and 2017, respectively. The remaining debt discount related to warrant expiration date extensions totals $789,340 and will be amortized through December 31, 2019.

NOTE 3 – Private Placements

September 2017 Private Placement

On September 11, 2017, the Company initiated and on September 29, 2017, completed a self-directed offering of 821,600 units at a price of $3.11 per unit for $2,555,176 in aggregate proceeds (the “September 2017 Private Placement”). The unit price was based on a 15% discount to the average of the 30-day closing price (last day being Friday September 8, 2017) of the Company's common stock as reported on the OTCQB. Each unit consisted of one share of common stock and one Series S Stock Purchase Warrant to purchase one (1) share of common stock at an exercise price of $3.42 per share through September 29, 2022. The warrants may be exercised on a cashless basis. All the units were purchased by unrelated parties.

The relative fair value of the common stock was estimated to be $1,540,000. The relative fair value of the Series S Warrants was estimated to be $1,015,000 as determined based on the relative fair value allocation of the proceeds received. The Series S Warrants were valued using the Black-Scholes option pricing model using the following variables: market price of common stock - $3.95 per share; estimated volatility – 77.96%; 5-year risk free interest rate – 1.71%; expected dividend rate - 0% and expected life - 5 years.

NOTE 4 – Common Stock and Warrants

Common Stock

At May 31, 2018, the Company had 300,000,000 authorized shares of common stock with a par value of $0.001 per share, 36,292,656 shares of common stock outstanding and 2,550,085 shares reserved for issuance under the Company’s 2006 Long-Term Incentive Plan (the “2006 Plan”) that provides for the grant of stock options to employees, directors, officers and consultants (See “NOTE 5 - Stock Options”).

During the nine months ended May 31, 2018, we entered into the following securities related transactions:

· On September 29, 2017, the Company completed the September 2017 Private Placement of 821,600 units at a price of $3.11 per unit for $2,555,176 in aggregate proceeds. Each unit consisted of one share of common stock and one Series S Stock Purchase Warrant to purchase one (1) share of common stock at an exercise price of $3.42 per share through September 29, 2022. The warrants may be exercised on a cashless basis (See “NOTE 3 – Private Placements”).

· On November 21, 2017 each director was granted 40,000 shares of common stock for a total issuance of 160,000 shares of common stock valued at $4.87 per share, the fair market value of our common stock on the date of issuance. Additionally, on November 21, the Company issued Jatinder Bhogal, Director, an additional 50,000 shares valued at $4.87 per share. 75% of the 210,000 issued shares are subject to a one-year lock-up.

· From September 6, 2017 through October 30, 2017, holders of our Series O Warrants exercised 80,000 warrants at an exercise price of $3.10 per share resulting in $248,000 to the Company and the issuance of 80,000 shares of common stock.

· On September 7, 2017, John Conklin, the Company’s President & CEO, exercised 100,000 stock purchase options on a cashless basis resulting in the issuance of 46,097 shares of common stock. On January 4, 2018, Mr. Conklin exercised 50,000 stock purchase options on a cashless basis resulting in the issuance of 34,013 shares of common stock.

11

 

· On December 28, 2017, Alastair Livesey, a Company Director, exercised 36,667 stock purchase options on a cashless basis resulting in the issuance of 19,067 shares of common stock.

· From September 7, 2017 through April 13, 2018, three other individuals exercised a total of 105,000 stock purchase options on a cashless basis resulting in the issuance of 46,985 shares of common stock.

· On September 7, 2017, the Investor exercised their outstanding Series Q Warrant to purchase up to 468,750 shares of the Company’s common stock on a cashless basis, resulting in the issuance of 189,940 shares of common stock.

· On September 7, 2017, a third party exercised their outstanding Series Q Warrant to purchase up to 468,750 shares of the Company’s common stock on a cashless basis, resulting in the issuance of 189,940 shares of common stock.

· On December 28, 2017, a third party exercised their outstanding Series R Warrant to purchase up to 468,750 shares of the Company’s common stock on a cashless basis, resulting in the issuance of 285,823 shares of common stock.

· From December 1, 2017 through April 30, 2018, holders of our Series P Warrants exercised 39,500 warrants at an exercise price of $3.70 per share resulting in $146,150 to the Company and the issuance of 39,500 shares of common stock.

Warrants

Each of the Company’s warrants outstanding entitles the holder to purchase one share of the Company’s common stock for each warrant share held. Other than the Series O Warrants and Series P Warrants, all of the following warrants may be exercised on a cashless basis. A summary of the Company’s warrants outstanding and exercisable as of May 31, 2018 and August 31, 2017 is as follows:

	Shares of Common Stock Issuable from Warrants Outstanding as of				Weighted
	May 31,		August 31,		Average
Description	2018		2017		Exercise Price		Expiration
Series M		246,000		246,000	$	2.34	December 31, 2022
Series N		767,000		767,000	$	3.38	December 31, 2022
Series O		-		618,000	$	3.10	October 31, 2017
Series P		213,500		309,000	$	3.70	December 31, 2022
Series Q		-		937,500	$	3.20	December 31, 2022
Series R		468,750		937,500	$	4.00	December 31, 2022
Series S-A		300,000		300,000	$	2.53	December 31, 2022
Series S		821,600		-	$	3.42	September 29, 2022
Total		2,816,850		4,115,000

NOTE 5 - Stock Options

Stock option grants pursuant to the 2006 Plan vest either immediately or over one to five years and expire ten years after the date of grant. Stockholders previously approved 5,000,000 shares for grant under the 2006 Plan, of which 2,550,085 remain available for grant, 1,305,001 have been exercised in total and 629,677 net shares issued pursuant to the exercise of vested options from inception of the 2006 Plan through May 31, 2018. All shares approved for grant and subsequently forfeited are available for future grant. The Company does not repurchase shares to fulfill the requirements of options that are exercised and therefore issues new shares when options are exercised. The 2006 Plan was approved by stockholders on February 7, 2011 and expires according to its terms on February 7, 2021.

12

The Company employs the following key weighted-average assumptions in determining the fair value of stock options, using the Black-Scholes option pricing model and the simplified method to estimate the expected term of “plain vanilla” options:

	Nine Months Ended May 31,
	2018			2017
Expected dividend yield		–			–
Expected stock price volatility	83.43% – 83.55		%		81	%
Risk-free interest rate	2.27% - 2.33		%		2.03	%
Expected term (in years)		7.67			7.67
Exercise price	$4.87 - $5.35			$	3.28
Weighted-average grant date fair-value	$3.76 - $5.64			$	2.48

A summary of the Company’s stock option activity for the nine months ended May 31, 2018 and year ended August 31, 2017 and related information follows:

	Number of Shares Subject to Option Grants	Weighted Average Exercise Price ($)	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value ($)
Outstanding at August 31, 2016	720,001	3.06
Grants	1,535,000	2.71
Exercises	(130,000)	2.62
Outstanding at August 31, 2017	2,125,001	2.84
Grants	1,263,000	5.25
Forfeitures and cancellations	(1,805,000)	2.74
Exercises	(291,667)	3.32
Outstanding at May 31, 2018	1,291,334	5.22	9.33 years	45,550
Exercisable at May 31, 2018	263,334	5.02	8.44 years	35,150

The aggregate intrinsic value in the table above represents the total pretax intrinsic value for all “in-the-money” options (i.e. the difference between the Company’s closing stock price on the last trading day of the period covered by this report and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all in-the-money option holders exercised their vested options on May 31, 2018. The intrinsic value of the option changes based upon the fair market value of the Company’s common stock. Since the closing stock price was $4.50 on May 31, 2018 and 42,500 outstanding options have an exercise price below $4.50 per share, as of May 31, 2018, there is intrinsic value to the Company’s outstanding, in-the-money stock options, including 32,500 options that are exercisable and in-the-money.

On November 21, 2017, the Company granted 255,000 options to directors and employees with an exercise price of $4.87.

On December 27, 2017, the Company entered into an employment agreement with John Conklin pursuant to which Mr. Conklin was granted 1,008,000 stock purchase options with an exercise price of $5.35 per share, vesting at the rate of 1/48^th per month and exercisable on a cashless basis. Mr. Conklin’s prior employment agreement expired on December 31, 2017 resulting in the forfeiture of 300,000 options with a performance condition that was not achieved.

During the nine months ended May 31, 2018, there were 1) 291,667 options exercised on a cashless basis resulting in the issuance of 146,162 shares of common stock, and 2) 5,000 unvested options forfeited resulting in a reduction to stock compensation expense of $5,157. The aggregate intrinsic value of the options exercised was $1,045,135.

13

During the year ended August 31, 2017, there were 130,000 options exercised on a cashless basis resulting in the issuance of 46,520 shares of common stock. The aggregate intrinsic value of the options exercised was $186,500.

On November 15, 2016, the Company granted 35,000 options to two employees with an exercise price of $3.28.

On July 7, 2017, the Company finalized and executed two consulting agreements with third parties to provide business development services. The terms and conditions of each consulting agreement are similar and provide for combined compensation of $26,000 per month in cash and the grant of 1,500,000 common stock purchase options with an exercise price of $2.70 per share, and which vest upon the achievement of performance milestones and upon Board approval. The 1,500,000 stock options granted to consultants had a grant date fair value of $1.84 per option. During May 2018, the Company terminated the consulting agreements. The Company determined that the consultants did not achieve the performance milestones resulting in the cancelation of the 1,500,000 options.

The following table sets forth the share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time, that were recorded in the Company’s Consolidated Statements of Operations for the three and nine months ended May 31, 2018 and 2017:

	Three Months Ended				Nine Months Ended
	May 31,				May 31,
	2018		2017		2018		2017
Stock Compensation Expense:
SG&A	$	215,695	$	26,667	$	796,371	$	102,589
R&PD		251,529		11,695		545,307		68,935
Total	$	467,224	$	38,362	$	1,341,678	$	171,524

As of May 31, 2018, the Company had $5,315,777 of unrecognized compensation cost related to unvested stock options which is expected to be recognized over a period of 3.75 years.

The following table summarizes information about stock options outstanding and exercisable at May 31, 2018: 

	Stock Options Outstanding			Stock Options Exercisable
Range of Exercise Prices	Number of Shares Subject to Outstanding Options	Weighted Average Contractual Life (years)	Weighted Average Exercise Price	Number of Shares Subject To Options Exercise	Weighted Average Remaining Contractual Life (Years)	Weighted Average Exercise Price
3.28	7,500	8.46	3.28	7,500	8.46	3.28
3.46	35,000	7.60	3.46	25,000	7.60	3.46
4.87	207,500	9.48	4.87	92,500	9.48	4.87
5.35	1,008,000	9.59	5.35	105,000	9.59	5.35
5.94	33,334	2.57	5.94	33,334	2.57	5.94
Total	1,291,334	9.33	$5.22	263,334	8.44	$5.02

14

NOTE 6 - Net Loss Per Share

During the three and nine months ended May 31, 2018 and 2017, the Company recorded a net loss. Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. The Company has not included the effects of warrants, stock options and convertible debt on net loss per share because to do so would be antidilutive.

Following is the computation of basic and diluted net loss per share for the three and nine months ended May 31, 2018 and 2017:

	Three Months Ended May 31,						Nine Months Ended May 31,
	2018			2017			2018			2017
Basic and Diluted EPS Computation
Numerator:
Loss available to common stockholders'	$	(1,444,896	)	$	(1,202,337	)	$	(5,633,511	)	$	(4,211,138	)
Denominator:
Weighted average number of common shares outstanding		36,270,592			33,810,348			35,924,340			30,347,594
Basic and diluted EPS	$	(0.04	)	$	(0.04	)	$	(0.16	)	$	(0.14	)
The shares listed below were not included in the computation of diluted losses
per share because to do so would have been antidilutive for the periods presented:
Stock options		1,291,334			625,001			1,291,334			625,001
Warrants		2,816,850			3,944,000			2,816,850			3,944,000
Convertible debt		3,084,175			2,820,966			3,084,175			2,820,966
Warrants issuable upon conversion of debt (See "NOTE 2 - Debt" above)		3,084,175			2,820,966			3,084,175			2,820,966
Total shares not included in the computation of diluted losses per share		10,276,534			10,210,933			10,276,534			10,210,933

NOTE 7 - Related Party Transactions

A related party with respect to the Company is generally defined as any person (i) (and, if a natural person, inclusive of his or her immediate family) that holds 10% or more of the Company’s securities, (ii) that is part of the Company’s management, (iii) that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

The law firm of Satterlee Stephens LLP (“Satterlee”), of which Joseph Sierchio, one of the Company’s directors, is a partner, provides counsel to the Company. Mr. Sierchio is the Company’s primary attorney. Fees billed by Satterlee during the three months ended May 31, 2018 and 2017, totaled $74,198 and $101,138, respectively, and $220,032 and $252,693 during the nine months ended May 31, 2018 and 2017. At May 31, 2018 and August 31, 2017, the Company owed Satterlee $50,286 and $105,184, respectively, which is included in accounts payable. Mr. Sierchio continues to serve as a director of the Company.

On August 7, 2017, the Company appointed Jatinder Bhogal to the Board of Directors. Mr. Bhogal has provided consulting services to the Company through his wholly owned company, Vector Asset Management, Inc., pursuant to a Consulting Agreement dated February 1, 2014 as amended on November 11, 2016. Pursuant to the Consulting Agreement, Mr. Bhogal receives compensation of $5,000 per month. In connection with the Consulting Agreement, during the three months ended May 31, 2018 and 2017, the Company recognized expense $15,000 and $15,000, respectively, and $45,000 and $45,000 of expense during the nine months ended May 31, 2018 and 2017, respectively.

On November 3, 2017, the Company entered into the Third Amendment to the 2013 Bridge Loan Agreement and the Third Amendment to the 2015 Bridge Loan Agreement with the Investor pursuant to which the Company and the Investor agreed to extend the maturity date to December 31, 2019. Pursuant to the Third Amendment to the 2013 Bridge Loan Agreement and the Third Amendment to the 2015 Bridge Loan Agreement, the rate of interest increased to 10.5% and the following warrants, held by the Investor, had their maturity date extended to December 31, 2022: a) Series M Warrant to purchase 246,000 shares; b) Series N Warrant to purchase 767,000 shares; c) Series P Warrant to purchase 213,500 shares; d) Series R Warrant to purchase 468,750; and e) Series S-A Warrant to purchase 300,000 shares. As a result of extending the expiration date of the above warrants to December 31, 2022, the Company recognized an additional debt discount to the 2013 Note of $1,074,265 as of November 3, 2017. For additional information related to our warrants, please see “NOTE 4 – Common Stock and Warrants”. For additional information related to our debt, please see “NOTE 2 – Debt”.

All related party transactions are recorded at the exchange amount established and agreed to between related parties and are in the normal course of business.

NOTE 8 – Subsequent Events

Management has reviewed material events subsequent of the period ended May 31, 2018 and prior to the filing of financial statements in accordance with FASB ASC 855 “Subsequent Events”.

15

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This Report on Form 10-Q contains forward-looking statements which involve assumptions and describe our future plans, strategies, and expectations, and are generally identifiable by use of words such as “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project,” or the negative of these words or other variations on these words or comparable terminology. These statements are expressed in good faith and based upon a reasonable basis when made, but there can be no assurance that these expectations will be achieved or accomplished.

Such forward-looking statements include statements regarding, among other things, (a) the potential markets for our technologies, our potential profitability, and cash flows, (b) our growth strategies, (c) expectations from our ongoing research and development activities, (d) anticipated trends in the technology industry, (e) our future financing plans, and (f) our anticipated needs for working capital. This information may involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from the future results, performance, or achievements expressed or implied by any forward-looking statements. These statements may be found under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” as well as in this Form 10-Q generally. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors, including, without limitation, the matters described in this Form 10-Q generally. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this filing will in fact occur. In addition to the information expressly required to be included in this filing, we will provide such further material information, if any, as may be necessary to make the required statements, in light of the circumstances under which they are made, not misleading.

Although forward-looking statements in this report reflect the good faith judgment of our management, forward-looking statements are inherently subject to known and unknown risks, business, economic and other risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this report, other than as may be required by applicable law or regulation. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect our actual results may vary materially from those expected or projected.

Except where the context otherwise requires and for purposes of this Form 10-Q only, “we,” “us,” “our,” “Company,” “our Company,” and “SolarWindow” refer to SolarWindow Technologies, Inc., a Nevada corporation, and its consolidated subsidiaries.

Overview

We are a pre-revenue company developing proprietary SolarWindow™ transparent electricity generating coatings that can be applied to glass, flexible glass and plastic surfaces. Our SolarWindow™ transparent electricity-generating coatings and technology is capable of harvesting light energy from the sun and artificial sources and could potentially be used on any of the more than 85 million commercial and residential buildings in the United States alone. Our SolarWindow™ technology is the subject of ninety (90) pending U.S. and international patent and trademark filings. These filings consist of sixty (60) U.S. and international patent and thirty (30) trademark applications for our electricity-generating coating and SolarWindow™ technology development efforts.

The development of our SolarWindow™ technology continues to advance under the Stevenson-Wydler Cooperative Research and Development Agreement (the “NREL CRADA”) with the Alliance for Sustainable Energy, LLC (the “Alliance for Sustainable Energy”), which is the operator of The National Renewable Energy Laboratory (“NREL”); and the award of the Company’s first-ever advanced materials manufacturing Cooperative Research and Development Agreement (CRADA) from the U.S. Department of Energy (DOE) Office of Energy Efficiency and Renewable Energy’s (EERE) Advanced Manufacturing Office (AMO).

16

On August 2, 2017, we entered into a Process Integration and Production Agreement (PIPA) with TriView Glass Industries, LLC (“Triview”). Triview is a glass fabricator operating a manufacturing facility in City of Industry, California. The purpose and primary goals of agreement are to:

1.	establish commercial scale manufacturing methodologies and processes to fabricate products based on WNDW technologies and
2.	integrate SolarWindow™ process technologies into the Triview manufacturing process, to fabricate specific transparent electricity-generating SolarWindow™ Products.

The Company has validated our SolarWindow™ coatings inside a rigorous autoclave system for window glass lamination at Triview. Layered with SolarWindow™ electricity-generating liquid coatings, glass modules were subjected to the extremely high heat and pressure of autoclave equipment located at the fabricator’s facility. Despite being subjected to harsh pressure and temperature conditions, subsequent performance testing confirmed that the SolarWindow™ modules continued to produce power. This is an important milestone for the commercialization of SolarWindow products, showing that our PV layers are compatible with autoclave production equipment.

We have achieved significant breakthroughs and overcome major technical challenges in the development of our SolarWindow™ technology, including the ability to generate electricity on glass while remaining transparent and the application of our coatings on to glass at room temperature and pressure.

A brief list of some of our more important milestones includes:

· SolarWindow has been awarded a Grant by the U.S. Department of Energy, for Advanced Manufacturing. The Company was awarded the CRADA after submitting a proposal outlining its process technologies and fabrication methods to the DOE’s Roll-to-Roll Advanced Materials Manufacturing Consortium, led by Oak Ridge National Laboratory (ORNL) and partnering with Argonne National Laboratory (ANL), Lawrence Berkeley National Laboratory (LBNL), and the National Renewable Energy Laboratory (NREL). The CRADA will be carried out with the DOE by SolarWindow, ANL, and NREL.

· the Company has set a new performance record for power efficiency with a 34% increase in performance over previous generations of its transparent electricity-generating glass. Performance results are based on independent testing and certification of SolarWindow™ devices by the U.S. Department of Energy’s National Renewable Energy Laboratory (NREL) Device Performance Measurement Laboratory.

· our SolarWindow™ transparent electricity-generating glass modules were successfully processed through the rigorous autoclave system for window glass lamination at a commercial window fabricator;

· successfully completed freeze/thaw performance testing necessary for the commercialization of our transparent electricity-generating coatings; modules were subjected to more than 200 freeze/thaw cycles, which yielded favorable performance results of the edge sealing processes and minimal impact on the device electrical performance;

· expanded product development and successfully applied our electricity-generating coatings onto flexible glass – as thin as a business card (only 0.1-millimeter-thick) – that is flexible enough to be bent without breaking or cracking;

· entered into the NREL CRADA which is still in effect;

· filed sixty (60) U.S. and international patent and thirty (30) trademark applications for our electricity-generating coating and SolarWindow™ technology development efforts;

17

· expanded the use of our SolarWindow™ coatings to include two new product lines for commercial and military aircraft, and the safety and security of military pilots;

· generated electricity on flexible plastic using novel see-through SolarWindow™ coatings;

· developed new SolarWindow™ coatings with increased transparency and improved color;

· produced the largest OPV device ever fabricated at NREL in the institute’s history; and

· successfully collected and transported electricity using a virtually ‘invisible’ conductive wiring system developed for SolarWindow™;

We are currently developing “SolarWindow™ Products” derived from our SolarWindow™ technology designed to address several potential markets, including:

· SolarWindow™ – Commercial – A flat glass product for installation in new commercial towers under construction and replacement windows;

· SolarWindow^TM – Structural Glass – Structural glass walls and curtains for tall structures;

· SolarWindow^TM – Architectural Glass – Textured and decorative interior glass walls, room dividers, etc.;

· SolarWindow™ – Residential – A window glass for installation in new residential homes under construction and replacement windows;

· SolarWindow™ – Flex – Flexible glass and plastic films which may be applied directly to different for curved and non-flat surfaces in automotive, aircraft, and military application; and

· SolarWindow™ Retrofit Veneer - Transparent, tinted, and flexible veneers that installers can apply directly on to existing, previously installed, window glass.

Our focus is on the development and deployment of SolarWindow™ glass products. We have working prototypes, which we share with our product development, manufacturing, and commercialization partners in the pursuit of commercially viable first-to-market products.

We do not currently have any commercial products and there is no assurance that we will successfully be able to design, develop, manufacture, or sell any commercial products in the future. Our product development programs involve ongoing R&D and product development efforts, and the commitment of significant resources to support the extensive invention, design, engineering, testing, prototyping, and intellectual property initiatives carried-out by our contract engineers, scientists, and consultants.

We plan to market any SolarWindow™ products that we commercialize through co-marketing and co-promotion, licensing, and distribution arrangements with third-party collaborators, such as Triview, to advance the technical development and subsequent commercialization of our SolarWindow™ products. We are actively seeking additional technology and product licensing contracts; joint venture arrangements; and manufacturing process integration relationships with commercial partners and industry; and organizations which have established technical competencies, market reach, and mature distribution networks in the solar PV, building-integrated PV, and alternative and renewable energy market industries. We believe that this approach could provide immediate access to existing distribution channels which can increase market penetration and commercial acceptance of our products, and enable us to avoid expending significant funds for development of a large sales and marketing organization.

18

We cannot accurately predict the amount of funding or the time required to successfully commercialize or fabricate SolarWindow™ products. The actual cost and time required to commercialize our SolarWindow™ technology may vary significantly depending on, among other things, the results of our product development efforts; the cost of developing, acquiring, or licensing various enabling technologies; changes in the focus and direction of our business or product development plans; competitive and technological advances; the cost of patent filing, prosecuting, defending and enforcing claims; demonstrating compliance with regulations and standards; and manufacturing, marketing and other costs that may be associated with product fabrication. Because of this uncertainty, even if financing is available to us, we may secure insufficient funding to effectuate our business and/or product development plans.

As of May 31, 2018, we had working capital of $1,281,807 and cash of $1,191,587. Based upon current and near term anticipated level of operations and expenditures, we believe that cash on hand should be sufficient to enable us to continue operations through January 2019. The Company’s SolarWindow™ research and product development programs involve ongoing efforts, and the commitment of significant resources to support the extensive invention, design, engineering, testing, prototyping, and intellectual property initiatives carried-out by its contract engineers, scientists, and consultants. If the Company fails to secure, on a timely basis, adequate additional funding it may not be able to continue its operations beyond January, 2019.

Management recognizes that in order for us to meet our capital requirements, and continue to operate, additional financing will be necessary. We expect to raise additional funds through private or public equity investment in order to expand the range and scope of our business operations. We will seek access to private or public equity markets but there is no assurance that such additional funds will be available for us to finance our operations on acceptable terms, if at all. If we are unable to raise additional capital or generate positive cash flow, it is unlikely that we will be able to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Research and Related Agreements

We are a party to certain agreements related to the development of our SolarWindow™ technology.

Process Integration and Production Agreement with TriView Glass Industries

On August 2, 2017, we entered into the PIPA Agreement with TriView. Triview is a glass fabricator operating a manufacturing facility in City of Industry, California. The purpose and primary goals of agreement are to:

1.	establish commercial scale manufacturing methodologies and processes to fabricate products based on SolarWindowTM technologies and
2.	integrate SolarWindow™ technologies into the Triview manufacturing process, to fabricate specific SolarWindow™ transparent electricity-generating glass products.

Stevenson-Wydler Cooperative Research and Development Agreement with the Alliance for Sustainable Energy

On March 18, 2011, we entered into the NREL CRADA with Alliance for Sustainable Energy, the operator of the NREL under its U.S. Department of Energy contract to advance the commercial development of the SolarWindow™ technology. Under terms of the NREL CRADA, NREL researchers will make use of our exclusive intellectual property (“IP”), newly developed IP, and NREL’s background IP in order to work towards specific product development goals. Under the terms of the NREL CRADA, we agreed to reimburse Alliance for Sustainable Energy for filing fees associated with all documented, out-of-pocket costs directly related to patent application preparation and filings, and maintenance of the patent applications.

On January 16, 2013, we entered into a modification to the NREL CRADA for the purpose of extending the date pursuant to which NREL’s researchers will make use of our exclusive IP and NREL’s background IP.

19

On March 6, 2013, we entered into Phase II of our NREL CRADA with Alliance for Sustainable Energy. Under the terms of the agreement, researchers will additionally work towards:

· further improving SolarWindow™ technology efficiency and transparency;

· optimizing electrical power (current and voltage) output;

· optimizing the application of the active layer coatings which make it possible for SolarWindow™ coatings to generate electricity on glass surfaces;

· developing improved electricity-generating coatings by enhancing performance, processing, reliability, and durability;

· optimizing SolarWindow™ coating performance on flexible substrates; and

· developing high speed and large area roll-to-roll (R2R) and sheet-to-sheet (S2S) coating methods required for commercial-scale BIPV products and windows.

On December 28, 2015, we entered into another modification of the CRADA (the “Modification”) to the NREL CRADA with Alliance for Sustainable Energy, previously entered into between us and NREL. The purpose of the Modification was to extend the date pursuant to which NREL’s researchers work towards specific product development goals. On November 21, 2017 the Company entered into a No Cost Time Extension (“NCTE”) under the NREL CRADA with the Alliance for Sustainable Energy. Under the terms of the NCTE, all terms and conditions of the CRADA remain in full force and effect without change, with a new completion date of December 21, 2018. Specifically, we are preparing to commercialize our OPV-based SolarWindow™ transparent electricity-generating coatings for BIPV, and glass and flexible plastic applications. Under Modification, NREL and the Company will work jointly towards achieving specific commercialization goals and objectives. As of May 31, 2018, the Company made $134,139 of advances to Alliance for Sustainable Energy for work to be performed under the NREL CRADA, which is capitalized as deferred research and development costs on our balance sheet.

U.S. Department of Energy (DOE) Office of Energy Efficiency and Renewable Energy’s (EERE) Advanced Manufacturing Office (AMO) Cooperative Research and Development Agreement

The purpose of this project is to develop and demonstrate a unique high-throughput process methodology for semitransparent organic photovoltaic (OPV) modules compatible with high process speeds for many different advanced material manufacturing systems.

Results of Operations

Three and Nine Months Ended May 31, 2018 Compared with the Three and Nine Months Ended May 31, 2017

Operating Expenses

A summary of our operating expense for the three and nine months ended May 31, 2018 and 2017 follows:

	Three Months Ended May 31,				Increase /			Percentage
	2018		2017		(Decrease)			Change
Operating expense
Selling, general and administrative	$	386,087	$	493,790	$	(107,703	)		-22
Research and product development		337,457		283,096		54,361			19
Stock compensation		467,224		34,562		432,662			1,252
Total operating expense	$	1,190,768	$	811,448	$	379,320			47

	Nine Months Ended May 31,				Increase /
	2018		2017		(Decrease)			% Change
Operating expense
Selling, general and administrative	$	1,239,404	$	1,671,533	$	(432,129	)		-26
Research and product development		985,973		743,137		242,836			33
Stock compensation		2,364,379		565,124		1,799,255			318
Total operating expense	$	4,589,756	$	2,979,794	$	1,609,962			54

20

Selling, General and Administrative

Selling, general and administrative costs include all expenditures incurred other than research and development related costs, including costs related to personnel, professional fees, travel and entertainment, public company costs, insurance and other office related costs. The decrease during the three and nine months ended May 31, 2018 compared to the three and nine months ended May 31, 2017, was primarily due to a decrease in investor communications related fees and the increased allocation of internal costs to R&PD offset to a lesser extent by higher insurance costs.

Research and Product Development

Research and Product Development (“R&PD”) costs represent costs incurred to develop our SolarWindow™ technology and are incurred pursuant to our research agreements and agreements with other third-party providers and certain internal R&PD cost allocations. Payments under these agreements include salaries and benefits for R&PD personnel, allocated overhead, contract services and other costs. R&PD costs are expensed when incurred, except for non-refundable advance payments for future research and development activities which are capitalized and recognized as expense as the related services are performed. R&PD costs increased during the three and nine months ended May 31, 2018 compared to the three and nine months ended May 31, 2017 primarily as a result of increased product development, including improving SolarWindow™ technology efficiency and transparency; optimizing electrical power (current and voltage) output; and improving performance, processing, reliability, and durability of SolarWindow™ coatings.

Stock Compensation

The Company grants stock options to its Directors, employees and consultants and issues stock to its Directors. Stock compensation represents the expense associated with the amortization of our stock options and issuance of common stock. Expense associated with equity-based transactions is calculated and expensed in our financial statements as required pursuant to various accounting rules and is non-cash in nature. Stock compensation expense increased during the three and nine months ended May 31, 2018 compared to the three and nine months ended May 31, 2017 due to the grant of 1,255,000 options and issuance of 210,000 shares of common stock to our directors at market prices and fair values that exceeded the prior year due to our higher stock price. In the prior year, the Company issued 120,000 shares to the Board valued at $393,600 compared to the current year Board share issuance of 210,000 shares valued at $1,022,700. Additionally, in the prior year, the Company issued 35,000 stock purchase options with vesting related expense of $69,000 compared to the grant of 1,263,000 stock purchase options in the current year with vesting related expense of $1,313,000.

Other Income (Expense)

A summary of our other income (expense) for the three and nine months ended May 31, 2018 and 2017 follows:

	Three Months Ended May 31,
	2018			2017			Change
Other income (expense)
Interest expense	$	(128,706	)	$	(79,162	)	$	49,544
Accretion of debt discount		(125,422	)		(311,727	)		(186,305	)
Total other income (expense)	$	(254,128	)	$	(390,889	)	$	(136,761	)

	Nine Months Ended May 31,
	2018			2017			Change
Other income (expense)
Interest expense	$	(345,453	)	$	(231,626	)	$	113,827
Accretion of debt discount		(698,302	)		(999,718	)		(301,416	)
Total other income (expense)	$	(1,043,755	)	$	(1,231,344	)	$	(187,589	)

“Interest expense” relates to the stated interest of our outstanding debt. “Accretion of debt discount” represents the accretion of the discount applied to our outstanding debt as a result of the issuance and modification of detachable warrants and the beneficial conversion feature contained in our notes. Pursuant to the third amendment to both outstanding promissory notes, the maturity date was extended to December 31, 2019 and the interest rate increased from 7% to 10.5% resulting in an increase to the amount of interest expense recognized during the three and nine months ended May 31, 2018 compared to the same prior year periods.

21

Liquidity and Capital Resources

We have a retained deficit of $44,663,263 through May 31, 2018. Included in the deficit are non-cash expenses totaling $19,555,941 relating to the issuance of stock for services, compensatory stock options, warrants granted for value and accretion of debt discount. Due to the “start-up” nature of our business, we expect to incur losses as we continue development of our technologies and products.

These conditions raise substantial doubt about our ability to continue as a going concern beyond January, 2019. Management recognizes that in order for us to meet our capital requirements, and continue to operate, additional financing will be necessary. We expect to raise additional funds through private or public equity investment in order to maintain and/or expand the range and scope of our business operations; however, there is no assurance that such additional funds will be available for us on a timely basis or acceptable terms, if at all. If we are unable to raise additional capital when needed or generate positive cash flow, it is unlikely that we will be able to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Our principal source of liquidity is cash in the bank. On May 31, 2018, we had a cash and cash equivalent balance of $1,191,587. We have financed our operations primarily from the sale of equity and debt securities. We currently do not have any agreements with any third party regarding a potential financing.

Net cash used in operating activities was $2,426,011 during the nine months ended May 31, 2018, compared to net cash used in operating activities of $2,174,647 during the nine months ended May 31, 2017. Cash used in operating activities increased during the nine months ended May 31, 2018 due to less cash used for investor communications and professional fees offset by higher product development related costs.

Net cash used in investing activities was $2,581 during the nine months ended May 31, 2018 compared to net cash used in investing activities of $45,547 during the nine months ended May 31, 2017. Cash used in investing activities decreased during the nine months ended February 28, 2018 due to no R&PD equivalent equipment purchases made in the current year compared to the prior year.

Net cash provided by financing activities was $2,949,326 during the nine months ended May 31, 2018, compared to cash used of $18,146 during the nine months ended May 31, 2017. Cash provided by financing activities during the nine months ended May 31, 2018 was from the exercise of 80,000 Series O Warrants for proceeds of $248,000; the exercise of 39,500 Series P Warrants for proceeds of $146,150 and the September 29, 2017 private placement of 821,600 units of our securities resulting in proceeds of $2,555,176. Cash used by financing activities during the nine months ended May 31, 2017 was from the re-payment of the bridge loan.

Other Contractual Obligations

In addition to our contractual obligations under the research agreements, as of May 31, 2018, we have lease payments of $1,200 each month under our month-to-month corporate office operating lease.

22

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Recently Issued Accounting Pronouncements

See Note 1 to our Consolidated Financial Statements for more information regarding recent accounting pronouncements and their impact to our consolidated results of operations and financial position.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this quarterly report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that as of May 31, 2018, that our disclosure controls and procedures were effective such that the information required to be disclosed in our United States Securities and Exchange Commission (the “SEC”) reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

23

PART II – OTHER INFORMATION

Item 6. Exhibits

Exhibit No.	Description of Exhibit
4.1	Form of Series S Stock Purchase Warrant dated September 29, 2017 (Incorporated by reference to Form 8-K filed on September 29, 2017)
4.2	Form of Registration Rights Agreement dated September 29, 2017 (Incorporated by reference to Form 8-K filed on September 29, 2017)
4.3	Form of Regulation S Subscription Agreement for Units (Incorporated by reference to Form 8-K filed on September 29, 2017)
4.4	Amendment to the 2014 Amended Bridge Loan Agreement dated November 3, 2017 (Incorporated by reference to Form 8-K filed on November 9, 2017)
4.5	Third Amendment to the 2015 Bridge Loan Agreement dated November 3, 2017 (Incorporated by reference to Form 8-K filed on November 9, 2017)
10.1	Employment Agreement with John Conklin dated as of December 27, 2017 (Incorporated by reference to Form 8-K filed on January 3, 2018
31.1	Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1	Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
101.INS	XBRL Instance Document**
101.SCH	XBRL Taxonomy Extension Schema Document**
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document**
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document**
101.LAB	XBRL Taxonomy Extension Label Linkbase Document**
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document**

____________________ 

*Filed herewith

** Furnished herewith. XBRL (eXtensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

24

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 

	SolarWindow Technologies, Inc.                       (Registrant)
Date: July 16, 2018	By:	/s/ John A. Conklin
		John A. Conklin
		Chief Executive Officer, Chief Financial Officer and Director
		(Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer)

 25

EX-31.1

EXHIBIT 31.1

CERTIFICATION PURSUANT TO RULE 13A-14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John A. Conklin, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of SolarWindow Technologies, Inc. (the “Registrant”);
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	As the registrant’s certifying officer I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. As the registrant's certifying officer I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

  

Date: July 16, 2018	By:	/s/ John A. Conklin
		John A. Conklin
		Chief Executive Officer, Chief Financial Officer and Director (Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer)

EX-32.1

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Quarterly Report on Form 10-Q of SolarWindow Technologies, Inc. for the fiscal quarter ending May 31, 2018, I, John Conklin, Chief Executive Officer and Chief Financial Officer of SolarWindow Technologies, Inc., hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge and belief, that:

1.	Such Quarterly Report on Form 10-Q for the fiscal quarter ending May 31, 2018, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.	The information contained in such Quarterly Report on Form 10-Q for the fiscal quarter ending May 31, 2018, fairly presents, in all material respects, the financial condition and results of operations of SolarWindow Technologies, Inc.

Date: July 16, 2018	By:	/s/ John A. Conklin
		John A. Conklin
		Chief Executive Officer, Chief Financial Officer and Director (Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer)

XML

Document and Entity Information - shares	9 Months Ended
	May 31, 2018	Jul. 12, 2018
Document And Entity Information
Entity Registrant Name	SolarWindow Technologies, Inc.
Entity Central Index Key	0001071840
Document Type	10-Q
Document Period End Date	May 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--08-31
Is Entity a Well-known Seasoned Issuer	No
Is Entity a Voluntary Filer	No
Is Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		36,292,656
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2018

XML

CONSOLIDATED BALANCE SHEETS - USD ($)	May 31, 2018	Aug. 31, 2017
Current assets
Cash and cash equivalents	$ 1,191,587	$ 670,853
Deferred research and development costs	134,139	91,204
Prepaid expenses and other current assets	44,764	16,698
Total current assets	1,370,490	778,755
Equipment, net of accumulated depreciation of $65,049 and $53,181, respectively	43,665	52,953
Total assets	1,414,155	831,708
Current liabilities
Accounts payable and accrued expenses	88,683	230,184
Total current liabilities	88,683	230,184
Bridge note payable to related party	600,000	600,000
Convertible promissory note payable to related party, net of discount of $789,340 and $413,377, respectively	2,210,660	2,586,623
Interest payable to related party	1,391,830	1,046,377
Total long term liabilities	4,202,490	4,233,000
Total liabilities	4,291,173	4,463,184
Commitments and contingencies
Stockholders' equity (deficit)
Preferred stock: $0.10 par value; 1,000,000 shares authorized, no shares issued and outstanding
Common stock: $0.001 par value; 300,000,000 shares authorized, 36,292,656 and 34,329,691 shares issued and outstanding at May 31, 2018 and August 31, 2017, respectively	36,293	34,330
Additional paid-in capital	41,749,952	35,363,946
Retained deficit	(44,663,263)	(39,029,752)
Total stockholders' equity (deficit)	(2,877,018)	(3,631,476)
Total liabilities and stockholders' equity (deficit)	$ 1,414,155	$ 831,708

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	May 31, 2018	Aug. 31, 2017
Current assets
Equipment, net of accumulated depreciation	$ 65,049	$ 53,181
Current liabilities
Convertible notes payable, Discount	$ 789,340	$ 413,377
Stockholders' equity
Preferred stock, par value	$ 0.10	$ 0.10
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	36,292,656	34,329,691
Common stock, shares outstanding	36,292,656	34,329,691

XML

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	May 31, 2018	May 31, 2017	May 31, 2018	May 31, 2017
Consolidated Statements Of Operations
Revenue
Operating expense
Selling, general and administrative	601,782	516,657	3,058,476	2,167,722
Research and product development	588,986	294,791	1,531,280	812,072
Total operating expense	1,190,768	811,448	4,589,756	2,979,794
Loss from operations	(1,190,768)	(811,448)	(4,589,756)	(2,979,794)
Other income (expense)
Interest expense	(128,706)	(79,162)	(345,453)	(231,626)
Accretion of debt discount	(125,422)	(311,727)	(698,302)	(999,718)
Total other income (expense)	(254,128)	(390,889)	(1,043,755)	(1,231,344)
Net loss	$ (1,444,896)	$ (1,202,337)	$ (5,633,511)	$ (4,211,138)
Basic and Diluted Loss per Common Share	$ (0.04)	$ (0.04)	$ (0.16)	$ (0.14)
Weighted average number of common shares outstanding - basic and diluted	36,270,592	33,810,348	35,924,340	30,347,594

XML

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Retained Deficit	Total
Beginning Balance, Shares at Aug. 31, 2016	28,500,221
Beginning Balance, Amount at Aug. 31, 2016	$ 28,500	$ 33,729,715	$ (33,676,327)	$ 81,888
July 2017 Private Placement units issued, Shares	300,000
July 2017 Private Placement units issued, Amount	$ 300	689,700		690,000
Stock based compensation related to stock issuances, Shares	138,904
Stock based compensation related to stock issuances, Amount	$ 139	448,463		448,602
Exercise of warrants for cash, Shares	129,000
Exercise of warrants for cash, Amount	$ 129	301,731		301,860
Exercise of warrants on a cashless basis, Shares	5,215,046
Exercise of warrants on a cashless basis, Amount	$ 5,215	(5,215)
Exercise of stock options on a cashless basis, Shares	46,520
Exercise of stock options on a cashless basis, Amount	$ 47	(47)
Stock based compensation due to common stock purchase options		199,599		199,599
Net loss			(5,353,425)	(5,353,425)
Ending Balance, Shares at Aug. 31, 2017	34,329,691
Ending Balance, Amount at Aug. 31, 2017	$ 34,330	35,363,946	(39,029,752)	(3,631,476)
Stock based compensation related to stock issuances, Shares	210,000
Stock based compensation related to stock issuances, Amount	$ 210	1,022,490		1,022,700
Exercise of warrants for cash, Shares	119,500
Exercise of warrants for cash, Amount	$ 120	394,030		394,150
Exercise of warrants on a cashless basis, Shares	665,703
Exercise of warrants on a cashless basis, Amount	$ 665	(665)
Exercise of stock options on a cashless basis, Shares	146,162
Exercise of stock options on a cashless basis, Amount	$ 146	(146)
Stock based compensation due to common stock purchase options		1,341,678		1,341,678
September 2017 Private Placement units issued, Shares	821,600
September 2017 Private Placement units issued, Amount	$ 822	2,554,354		2,555,176
Discount on convertible promissory note due to warrant modifications		1,074,265		1,074,265
Net loss			(5,633,511)	(5,633,511)
Ending Balance, Shares at May. 31, 2018	36,292,656
Ending Balance, Amount at May. 31, 2018	$ 36,293	$ 41,749,952	$ (44,663,263)	$ (2,877,018)

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	May 31, 2018	May 31, 2017
Cash flows from operating activities
Net loss	$ (5,633,511)	$ (4,211,138)
Adjustments to reconcile net loss to net cash flows from operating activities
Depreciation	11,869	9,835
Stock based compensation expense	2,364,378	565,124
Accretion of debt discount	698,302	999,718
Changes in operating assets and liabilities:
Decrease (increase) in deferred research and development costs	(42,935)	258,807
Decrease (increase) in prepaid expenses and other current assets	(28,066)	(32,606)
Increase (decrease) in accounts payable and accrued expenses	(141,501)	5,439
Increase (decrease) in interest payable	345,453	230,174
Net cash flows from operating activities	(2,426,011)	(2,174,647)
Cash flows from investing activity
Purchase of equipment	(2,581)	(45,547)
Net cash flows from investing activity	(2,581)	(45,547)
Cash flows from financing activities
Proceeds from the issuance of equity securities	2,949,326
Repayment of promissory note		(18,146)
Net cash flows from financing activities	2,949,326	(18,146)
Change in cash and cash equivalents	520,734	(2,238,340)
Cash and cash equivalents at beginning of period	670,853	2,509,215
Cash and cash equivalents at end of period	1,191,587	270,875
Supplemental disclosure of cash flow information:
Interest paid in cash		1,453
Income taxes paid in cash
Supplemental disclosure of non-cash transactions:
Discount on convertible promissory note due to to warrant modifications	$ 1,074,265

XML

Basis of Presentation, Organization, Recent Accounting Pronouncements and Going Concern

9 Months Ended

May 31, 2018

Notes to Financial Statements

NOTE 1 - Basis of Presentation, Organization, Recent Accounting Pronouncements and Going Concern

Basis of Presentation

The unaudited financial statements of SolarWindow Technologies, Inc. (the “Company”) as of May 31, 2018, and for the three and nine months ended May 31, 2018 and 2017, have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for interim financial reporting and include the Company’s wholly-owned subsidiaries, Kinetic Energy Corporation (“KEC”), and New Energy Solar Corporation (“New Energy Solar”). Accordingly, they do not include all of the disclosures required by accounting principles generally accepted in the United States for complete financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended August 31, 2017, as filed with the Securities and Exchange Commission as part of the Company’s Form 10-K. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the interim financial information have been included. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.

Organization

SolarWindow Technologies, Inc. was incorporated in the State of Nevada on May 5, 1998, under the name “Octillion Corp.” On December 2, 2008, the Company amended its Articles of Incorporation to effect a change of name to New Energy Technologies, Inc. Effective as of March 9, 2015, the Company amended its Articles of Incorporation to change its name to SolarWindow Technologies, Inc. to align the company name with its brand identity. The Company’s ticker symbol changed to WNDW.

Until the fourth quarter of the 2015 fiscal year, the Company was developing two sustainable electricity generating systems. These novel technologies are branded as SolarWindow™ and MotionPower™. On March 2, 2015, the Company announced its exclusive focus on SolarWindow™.

The Company’s SolarWindow™ technology harvests light energy from the sun and artificial sources to generate electricity from a transparent coating of organic photovoltaic solar cells applied to glass or plastics, creating a “photovoltaic” effect. Photovoltaics are best known as “solar panels” providing a method to generate electricity using solar cells to convert energy from the sun into a flow of electrons. Conventional PV power is generated by solar modules composed of interconnected mono- or poly-crystalline cells containing PV and electricity-conducting materials. These materials are usually opaque (i.e., not see-through) and only effectively generate electricity with sun light. The Company’s researchers have replaced these materials with a very thin layer of specially developed compounds that allow our SolarWindow™ technology to remain see-through or “transparent,” while generating electricity when exposed to either sun or artificial light.

Recent Accounting Pronouncements

In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a free-standing equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. Management is currently assessing the impact the adoption of ASU 2017-11 will have on the Company’s Consolidated Financial Statements.

In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting. The amendments in this Update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for public business entities for reporting periods for which financial statements have not yet been issued. Management is currently assessing the impact the adoption of ASU 2017-09 will have on the Company’s Consolidated Financial Statements.

In March 2016, the FASB issued ASU No. 2016-09, “Compensation-Stock Compensation: Improvements to Employee Share-Based Payment Accounting (Topic 718)”, which is intended to simplify several aspects of the accounting for share-based payment award transactions. The guidance is effective for our current fiscal year. The adoption of ASU 2016-09 did not have a material impact on the Consolidated Financial Statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842)”, which supersedes ASC Topic 840, Leases, and creates a new topic, ASC 842, Leases. The new guidance requires the recognition of lease assets and liabilities for operating leases with terms of more than 12 months. Presentation of leases within the consolidated statements of operations and consolidated statements of cash flows will be generally consistent with the current lease accounting guidance. The ASU is effective for reporting periods beginning after December 15, 2018, with early adoption permitted. The Company does not expect this accounting update to have a material effect on its Consolidated Financial Statements.

In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”). The standard requires that deferred tax assets and liabilities be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. ASU 2015-17 is effective for our current fiscal year. The adoption of ASU 2015-17 did not have a material impact on the Consolidated Financial Statements.

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”, to clarify the principles used to recognize revenue for all entities. In March 2016, the FASB issued ASU 2016-08 to further clarify the implementation guidance on principal versus agent considerations. The guidance is effective for annual and interim periods beginning after December 15, 2017. The Company does not expect this accounting update to have a material effect on its Consolidated Financial Statements.

The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion. The Company believes that none of the new standards will have a significant impact on its Consolidated Financial Statements.

Going Concern

The Company does not have any commercialized products, has not generated any revenue since inception and has sustained recurring losses and negative cash flows from operations since inception. Due to the “start-up” nature of our business, we expect to incur losses as we continue development of our products and technologies. As of May 31, 2018, the Company has incurred recurring operating losses since inception of $44,663,263. As of May 31, 2018, the Company had approximately $1,191,587 of cash on hand and current liabilities of $88,683. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which contemplates continuation of the Company as a going concern, which is dependent upon the Company’s ability to establish itself as a profitable business.

As of the date of filing of the Company’s most recent Form 10-K on November 22, 2017, based on management’s assessment, the Company had sufficient cash to meet its funding requirements for the next twelve months. However, currently, based upon the Company’s near term anticipated level of operations and expenditures, management believes that cash on hand should be sufficient to enable the Company to continue operations through January 2019 or approximately six months from the date of this quarterly report. In view of these conditions, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. These consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements.

The Company has negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The Company expects that it will need to continue to raise substantial additional capital to accomplish its business plan over the next several years, in line with previous expectations. The Company will seek additional funding through private equity or convertible debt. If adequate funds are not available on reasonable terms, or at all, it would result in a material adverse effect on the Company’s business, operating results, financial condition and prospects. In particular, the Company may be required to delay; reduce the scope of or terminate its research and development programs; sell rights to its SolarWindow™ technology and/or MotionPower™ technology, or other technologies or products based upon these technologies; or license the rights to these technologies or products on terms that are less favorable to the Company than might otherwise be available.

XML

Debt

9 Months Ended

May 31, 2018

Notes to Financial Statements

NOTE 2 - Debt

As of May 31, 2018 and August 31, 2017, the Company had the following outstanding debt balances:

	Issue	Maturity			Debt					Interest
	Date	Date	Principal		Discount			Balance		Payable
As of May 31, 2018:
March 2015 Loan as amended	3/4/2015	12/31/2019	$	600,000	$	-		$	600,000	$	166,510
2013 Note as amended	10/7/2013	12/31/2019		3,000,000		(789,340	)		2,210,660		1,225,320
			$	3,600,000	$	(789,340	)	$	2,810,660	$	1,391,830
As of August 31, 2017:
March 2015 Loan as amended	3/4/2015	12/31/2017	$	600,000	$	-		$	600,000	$	113,465
2013 Note as amended	10/7/2013	12/31/2017		3,000,000		(413,377	)		2,586,623		932,912
			$	3,600,000	$	(413,377	)	$	3,186,623	$	1,046,377

March 2015 Loan as Amended

On March 4, 2015, the Company entered into a Bridge Loan Agreement with 1420468 Alberta Ltd. (which has since been merged with and into Kalen Capital Corporation, a British Columbia corporation wholly-owned by our Chairman, Harmel S. Rayat (the “Investor”)). Pursuant the Bridge Loan Agreement, the Company borrowed $600,000 at an annual interest rate of 7% (the “March 2015 Loan”), compounded quarterly, with a default rate of 15%.

On November 3, 2017, the Company entered into the Third Amendment related to the March 2015 Loan pursuant to which the Company and the Investor amended the March 2015 loan to extend the maturity date to December 31, 2019. As consideration for the note extension, the interest rate was increased to 10.5%.

During the three months ended May 31, 2018 and 2017, the Company recognized $19,763 and $12,156, respectively, of interest expense. During the nine months ended May 31, 2018 and 2017, the Company recognized $53,045 and $35,462, respectively, of interest expense. During the three and nine months ended May 31, 2018, the Company recognized no debt discount accretion. During the three and nine months ended May 31, 2017, the Company recognized debt discount accretion of $0 and $74,702, respectively.

2013 Note as Amended

On October 7, 2013, the Company sold to the Investor an unsecured Convertible Promissory Note (the “2013 Note”) in the amount of $3,000,000 with 7% interest compounded quarterly. According to the terms of the amended 2013 Note, the Investor may elect to convert principal and accrued interest into units of the Company’s equity securities, with each Unit consisting of (a) one share of common stock; and (b) one Stock Purchase Warrant for the purchase of one share of common stock. The conversion price for each Unit is the lesser of (i) $1.37; or (ii) 70% of the 20 day average closing price of the Company’s common stock prior to conversion, subject to a floor of $1.00 with the exercise price of each Warrant being equal to 60% of the 20 day average closing price of the Company’s common stock prior to conversion. If issued, the Warrant included in the Units will be exercisable for a period of five years. As of May 31, 2018, if the investor elected to convert the entirety of amounts owing under the 2013 Note, the Company would be obligated to issue a warrant for the purchase of 3,084,175 shares of common stock.

On November 3, 2017, the Company entered into the Third Amendment related to the 2013 Note pursuant to which the Company and the Investor amended the 2013 Note to extend the maturity date to December 31, 2019. As consideration for the note extension, the interest rate was increased to 10.5% and all outstanding warrants held by the Investor had their maturity date extended to December 31, 2022, as described below, resulting in an additional debt discount of $1,074,265 as of November 3, 2017. The modification did not result in a gain or loss due to the related party nature of the transaction.

The maturity date of the remaining Series M Warrant to purchase 246,000 shares of common stock was extended from December 31, 2020 to December 31, 2022. The Company recorded $82,656 as a debt discount to recognize the increase in value for the extension of the expiration date.

The maturity date of the Series N Warrant to purchase 767,000 shares of common stock was extended from December 31, 2020 to December 31, 2022. The Company recorded $327,509 as a debt discount to recognize the increase in value for the extension of the expiration date.

The maturity date of the Series P Warrant to purchase 213,500 shares of common stock was extended from April 30, 2018 to December 31, 2022. The Company recorded $348,219 as a debt discount to recognize the increase in value for the extension of the expiration date.

The maturity date of the Series R Warrant to purchase 468,750 shares of common stock was extended from June 20, 2021 to December 31, 2022. The Company recorded $295,781 as a debt discount to recognize the increase in value for the extension of the expiration date.

The maturity date of the Series S-A Warrant to purchase 300,000 shares of common stock was extended from July 24, 2022 to December 31, 2022. The Company recorded $20,100 as a debt discount to recognize the increase in value for the extension of the expiration date.

Interest expense related to the 2013 Note, as amended, amounted to $108,943 and $67,006 during the three months ended May 31, 2018 and 2017, respectively. Interest expense amounted to $292,408 and $195,480 during the nine months ended May 31, 2018 and 2017, respectively.

Accretion of the debt discount related to the 2013 Note as amended amounted to $125,422 and $311,727 during the three months ended May 31, 2018 and 2017, respectively and $698,302 and $925,016 during the nine months ended May 31, 2018 and 2017, respectively. The remaining debt discount related to warrant expiration date extensions totals $789,340 and will be amortized through December 31, 2019.

XML

Private Placements

9 Months Ended

May 31, 2018

Notes to Financial Statements

NOTE 3 - Private Placements

September 2017 Private Placement

On September 11, 2017, the Company initiated and on September 29, 2017, completed a self-directed offering of 821,600 units at a price of $3.11 per unit for $2,555,176 in aggregate proceeds (the “September 2017 Private Placement”). The unit price was based on a 15% discount to the average of the 30-day closing price (last day being Friday September 8, 2017) of the Company's common stock as reported on the OTCQB. Each unit consisted of one share of common stock and one Series S Stock Purchase Warrant to purchase one (1) share of common stock at an exercise price of $3.42 per share through September 29, 2022. The warrants may be exercised on a cashless basis. All the units were purchased by unrelated parties.

The relative fair value of the common stock was estimated to be $1,540,000. The relative fair value of the Series S Warrants was estimated to be $1,015,000 as determined based on the relative fair value allocation of the proceeds received. The Series S Warrants were valued using the Black-Scholes option pricing model using the following variables: market price of common stock - $3.95 per share; estimated volatility – 77.96%; 5-year risk free interest rate – 1.71%; expected dividend rate - 0% and expected life - 5 years.

XML

Common Stock and Warrants

9 Months Ended

May 31, 2018

Notes to Financial Statements

NOTE 4 - Common Stock and Warrants

Common Stock

At May 31, 2018, the Company had 300,000,000 authorized shares of common stock with a par value of $0.001 per share, 36,292,656 shares of common stock outstanding and 2,550,085 shares reserved for issuance under the Company’s 2006 Long-Term Incentive Plan (the “2006 Plan”) that provides for the grant of stock options to employees, directors, officers and consultants (See “NOTE 5 - Stock Options”).

During the nine months ended May 31, 2018, we entered into the following securities related transactions:

· On September 29, 2017, the Company completed the September 2017 Private Placement of 821,600 units at a price of $3.11 per unit for $2,555,176 in aggregate proceeds. Each unit consisted of one share of common stock and one Series S Stock Purchase Warrant to purchase one (1) share of common stock at an exercise price of $3.42 per share through September 29, 2022. The warrants may be exercised on a cashless basis (See “NOTE 3 – Private Placements”).

· On November 21, 2017 each director was granted 40,000 shares of common stock for a total issuance of 160,000 shares of common stock valued at $4.87 per share, the fair market value of our common stock on the date of issuance. Additionally, on November 21, the Company issued Jatinder Bhogal, Director, an additional 50,000 shares valued at $4.87 per share. 75% of the 210,000 issued shares are subject to a one-year lock-up.

· From September 6, 2017 through October 30, 2017, holders of our Series O Warrants exercised 80,000 warrants at an exercise price of $3.10 per share resulting in $248,000 to the Company and the issuance of 80,000 shares of common stock.

· On September 7, 2017, John Conklin, the Company’s President & CEO, exercised 100,000 stock purchase options on a cashless basis resulting in the issuance of 46,097 shares of common stock. On January 4, 2018, Mr. Conklin exercised 50,000 stock purchase options on a cashless basis resulting in the issuance of 34,013 shares of common stock.

· On December 28, 2017, Alastair Livesey, a Company Director, exercised 36,667 stock purchase options on a cashless basis resulting in the issuance of 19,067 shares of common stock.

· From September 7, 2017 through April 13, 2018, three other individuals exercised a total of 105,000 stock purchase options on a cashless basis resulting in the issuance of 46,985 shares of common stock.

· On September 7, 2017, the Investor exercised their outstanding Series Q Warrant to purchase up to 468,750 shares of the Company’s common stock on a cashless basis, resulting in the issuance of 189,940 shares of common stock.

· On September 7, 2017, a third party exercised their outstanding Series Q Warrant to purchase up to 468,750 shares of the Company’s common stock on a cashless basis, resulting in the issuance of 189,940 shares of common stock.

· On December 28, 2017, a third party exercised their outstanding Series R Warrant to purchase up to 468,750 shares of the Company’s common stock on a cashless basis, resulting in the issuance of 285,823 shares of common stock.

· From December 1, 2017 through April 30, 2018, holders of our Series P Warrants exercised 39,500 warrants at an exercise price of $3.70 per share resulting in $146,150 to the Company and the issuance of 39,500 shares of common stock.

Warrants

Each of the Company’s warrants outstanding entitles the holder to purchase one share of the Company’s common stock for each warrant share held. Other than the Series O Warrants and Series P Warrants, all of the following warrants may be exercised on a cashless basis. A summary of the Company’s warrants outstanding and exercisable as of May 31, 2018 and August 31, 2017 is as follows:

	Shares of Common Stock Issuable from Warrants Outstanding as of				Weighted
	May 31,		August 31,		Average
Description	2018		2017		Exercise Price		Expiration
Series M		246,000		246,000	$	2.34	December 31, 2022
Series N		767,000		767,000	$	3.38	December 31, 2022
Series O		-		618,000	$	3.10	October 31, 2017
Series P		213,500		309,000	$	3.70	December 31, 2022
Series Q		-		937,500	$	3.20	December 31, 2022
Series R		468,750		937,500	$	4.00	December 31, 2022
Series S-A		300,000		300,000	$	2.53	December 31, 2022
Series S		821,600		-	$	3.42	September 29, 2022
Total		2,816,850		4,115,000

XML

Stock Options

9 Months Ended

May 31, 2018

Notes to Financial Statements

NOTE 5 - Stock Options

Stock option grants pursuant to the 2006 Plan vest either immediately or over one to five years and expire ten years after the date of grant. Stockholders previously approved 5,000,000 shares for grant under the 2006 Plan, of which 2,550,085 remain available for grant, 1,305,001 have been exercised in total and 629,677 net shares issued pursuant to the exercise of vested options from inception of the 2006 Plan through May 31, 2018. All shares approved for grant and subsequently forfeited are available for future grant. The Company does not repurchase shares to fulfill the requirements of options that are exercised and therefore issues new shares when options are exercised. The 2006 Plan was approved by stockholders on February 7, 2011 and expires according to its terms on February 7, 2021.

The Company employs the following key weighted-average assumptions in determining the fair value of stock options, using the Black-Scholes option pricing model and the simplified method to estimate the expected term of “plain vanilla” options:

	Nine Months Ended May 31,
	2018			2017
Expected dividend yield		–			–
Expected stock price volatility	83.43% – 83.55		%		81	%
Risk-free interest rate	2.27% - 2.33		%		2.03	%
Expected term (in years)		7.67			7.67
Exercise price	$4.87 - $5.35			$	3.28
Weighted-average grant date fair-value	$3.76 - $5.64			$	2.48

A summary of the Company’s stock option activity for the nine months ended May 31, 2018 and year ended August 31, 2017 and related information follows:

	Number of Shares Subject to Option Grants	Weighted Average Exercise Price ($)	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value ($)
Outstanding at August 31, 2016	720,001	3.06
Grants	1,535,000	2.71
Exercises	(130,000)	2.62
Outstanding at August 31, 2017	2,125,001	2.84
Grants	1,263,000	5.25
Forfeitures and cancellations	(1,805,000)	2.74
Exercises	(291,667)	3.32
Outstanding at May 31, 2018	1,291,334	5.22	9.33 years	45,550
Exercisable at May 31, 2018	263,334	5.02	8.44 years	35,150

The aggregate intrinsic value in the table above represents the total pretax intrinsic value for all “in-the-money” options (i.e. the difference between the Company’s closing stock price on the last trading day of the period covered by this report and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all in-the-money option holders exercised their vested options on May 31, 2018. The intrinsic value of the option changes based upon the fair market value of the Company’s common stock. Since the closing stock price was $4.50 on May 31, 2018 and 42,500 outstanding options have an exercise price below $4.50 per share, as of May 31, 2018, there is intrinsic value to the Company’s outstanding, in-the-money stock options, including 32,500 options that are exercisable and in-the-money.

On November 21, 2017, the Company granted 255,000 options to directors and employees with an exercise price of $4.87.

On December 27, 2017, the Company entered into an employment agreement with John Conklin pursuant to which Mr. Conklin was granted 1,008,000 stock purchase options with an exercise price of $5.35 per share, vesting at the rate of 1/48^th per month and exercisable on a cashless basis. Mr. Conklin’s prior employment agreement expired on December 31, 2017 resulting in the forfeiture of 300,000 options with a performance condition that was not achieved.

During the nine months ended May 31, 2018, there were 1) 291,667 options exercised on a cashless basis resulting in the issuance of 146,162 shares of common stock, and 2) 5,000 unvested options forfeited resulting in a reduction to stock compensation expense of $5,157. The aggregate intrinsic value of the options exercised was $1,045,135.

During the year ended August 31, 2017, there were 130,000 options exercised on a cashless basis resulting in the issuance of 46,520 shares of common stock. The aggregate intrinsic value of the options exercised was $186,500.

On November 15, 2016, the Company granted 35,000 options to two employees with an exercise price of $3.28.

On July 7, 2017, the Company finalized and executed two consulting agreements with third parties to provide business development services. The terms and conditions of each consulting agreement are similar and provide for combined compensation of $26,000 per month in cash and the grant of 1,500,000 common stock purchase options with an exercise price of $2.70 per share, and which vest upon the achievement of performance milestones and upon Board approval. The 1,500,000 stock options granted to consultants had a grant date fair value of $1.84 per option. During May 2018, the Company terminated the consulting agreements. The Company determined that the consultants did not achieve the performance milestones resulting in the cancelation of the 1,500,000 options.

The following table sets forth the share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time, that were recorded in the Company’s Consolidated Statements of Operations for the three and nine months ended May 31, 2018 and 2017:

	Three Months Ended				Nine Months Ended
	May 31,				May 31,
	2018		2017		2018		2017
Stock Compensation Expense:
SG&A	$	215,695	$	26,667	$	796,371	$	102,589
R&PD		251,529		11,695		545,307		68,935
Total	$	467,224	$	38,362	$	1,341,678	$	171,524

As of May 31, 2018, the Company had $5,315,777 of unrecognized compensation cost related to unvested stock options which is expected to be recognized over a period of 3.75 years.

The following table summarizes information about stock options outstanding and exercisable at May 31, 2018: 

	Stock Options Outstanding			Stock Options Exercisable
Range of Exercise Prices	Number of Shares Subject to Outstanding Options	Weighted Average Contractual Life (years)	Weighted Average Exercise Price	Number of Shares Subject To Options Exercise	Weighted Average Remaining Contractual Life (Years)	Weighted Average Exercise Price
3.28	7,500	8.46	3.28	7,500	8.46	3.28
3.46	35,000	7.60	3.46	25,000	7.60	3.46
4.87	207,500	9.48	4.87	92,500	9.48	4.87
5.35	1,008,000	9.59	5.35	105,000	9.59	5.35
5.94	33,334	2.57	5.94	33,334	2.57	5.94
Total	1,291,334	9.33	$5.22	263,334	8.44	$5.02

XML

Net Loss Per Share

9 Months Ended

May 31, 2018

Notes to Financial Statements

NOTE 6 - Net Loss Per Share

During the three and nine months ended May 31, 2018 and 2017, the Company recorded a net loss. Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. The Company has not included the effects of warrants, stock options and convertible debt on net loss per share because to do so would be antidilutive.

Following is the computation of basic and diluted net loss per share for the three and nine months ended May 31, 2018 and 2017:

	Three Months Ended May 31,						Nine Months Ended May 31,
	2018			2017			2018			2017
Basic and Diluted EPS Computation
Numerator:
Loss available to common stockholders'	$	(1,444,896	)	$	(1,202,337	)	$	(5,633,511	)	$	(4,211,138	)
Denominator:
Weighted average number of common shares outstanding		36,270,592			33,810,348			35,924,340			30,347,594
Basic and diluted EPS	$	(0.04	)	$	(0.04	)	$	(0.16	)	$	(0.14	)
The shares listed below were not included in the computation of diluted losses
per share because to do so would have been antidilutive for the periods presented:
Stock options		1,291,334			625,001			1,291,334			625,001
Warrants		2,816,850			3,944,000			2,816,850			3,944,000
Convertible debt		3,084,175			2,820,966			3,084,175			2,820,966
Warrants issuable upon conversion of debt (See "NOTE 2 - Debt" above)		3,084,175			2,820,966			3,084,175			2,820,966
Total shares not included in the computation of diluted losses per share		10,276,534			10,210,933			10,276,534			10,210,933

XML

Related Party Transactions

9 Months Ended

May 31, 2018

Notes to Financial Statements

NOTE 7 - Related Party Transactions

A related party with respect to the Company is generally defined as any person (i) (and, if a natural person, inclusive of his or her immediate family) that holds 10% or more of the Company’s securities, (ii) that is part of the Company’s management, (iii) that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

The law firm of Satterlee Stephens LLP (“Satterlee”), of which Joseph Sierchio, one of the Company’s directors, is a partner, provides counsel to the Company. Mr. Sierchio is the Company’s primary attorney. Fees billed by Satterlee during the three months ended May 31, 2018 and 2017, totaled $74,198 and $101,138, respectively, and $220,032 and $252,693 during the nine months ended May 31, 2018 and 2017. At May 31, 2018 and August 31, 2017, the Company owed Satterlee $50,286 and $105,184, respectively, which is included in accounts payable. Mr. Sierchio continues to serve as a director of the Company.

On August 7, 2017, the Company appointed Jatinder Bhogal to the Board of Directors. Mr. Bhogal has provided consulting services to the Company through his wholly owned company, Vector Asset Management, Inc., pursuant to a Consulting Agreement dated February 1, 2014 as amended on November 11, 2016. Pursuant to the Consulting Agreement, Mr. Bhogal receives compensation of $5,000 per month. In connection with the Consulting Agreement, during the three months ended May 31, 2018 and 2017, the Company recognized expense $15,000 and $15,000, respectively, and $45,000 and $45,000 of expense during the nine months ended May 31, 2018 and 2017, respectively.

On November 3, 2017, the Company entered into the Third Amendment to the 2013 Bridge Loan Agreement and the Third Amendment to the 2015 Bridge Loan Agreement with the Investor pursuant to which the Company and the Investor agreed to extend the maturity date to December 31, 2019. Pursuant to the Third Amendment to the 2013 Bridge Loan Agreement and the Third Amendment to the 2015 Bridge Loan Agreement, the rate of interest increased to 10.5% and the following warrants, held by the Investor, had their maturity date extended to December 31, 2022: a) Series M Warrant to purchase 246,000 shares; b) Series N Warrant to purchase 767,000 shares; c) Series P Warrant to purchase 213,500 shares; d) Series R Warrant to purchase 468,750; and e) Series S-A Warrant to purchase 300,000 shares. As a result of extending the expiration date of the above warrants to December 31, 2022, the Company recognized an additional debt discount to the 2013 Note of $1,074,265 as of November 3, 2017. For additional information related to our warrants, please see “NOTE 4 – Common Stock and Warrants”. For additional information related to our debt, please see “NOTE 2 – Debt”.

All related party transactions are recorded at the exchange amount established and agreed to between related parties and are in the normal course of business.

XML

Subsequent Events

9 Months Ended

May 31, 2018

Notes to Financial Statements

NOTE 8 - Subsequent Events

Management has reviewed material events subsequent of the period ended May 31, 2018 and prior to the filing of financial statements in accordance with FASB ASC 855 “Subsequent Events”.

XML

Basis of Presentation, Organization, Recent Accounting Pronouncements and Going Concern (Policies)

9 Months Ended

May 31, 2018

Basis Of Presentation Organization Recent Accounting Pronouncements And Going Concern

Basis of Presentation

The unaudited financial statements of SolarWindow Technologies, Inc. (the “Company”) as of May 31, 2018, and for the three and nine months ended May 31, 2018 and 2017, have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for interim financial reporting and include the Company’s wholly-owned subsidiaries, Kinetic Energy Corporation (“KEC”), and New Energy Solar Corporation (“New Energy Solar”). Accordingly, they do not include all of the disclosures required by accounting principles generally accepted in the United States for complete financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended August 31, 2017, as filed with the Securities and Exchange Commission as part of the Company’s Form 10-K. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the interim financial information have been included. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.

Organization

SolarWindow Technologies, Inc. was incorporated in the State of Nevada on May 5, 1998, under the name “Octillion Corp.” On December 2, 2008, the Company amended its Articles of Incorporation to effect a change of name to New Energy Technologies, Inc. Effective as of March 9, 2015, the Company amended its Articles of Incorporation to change its name to SolarWindow Technologies, Inc. to align the company name with its brand identity. The Company’s ticker symbol changed to WNDW.

Until the fourth quarter of the 2015 fiscal year, the Company was developing two sustainable electricity generating systems. These novel technologies are branded as SolarWindow™ and MotionPower™. On March 2, 2015, the Company announced its exclusive focus on SolarWindow™.

The Company’s SolarWindow™ technology harvests light energy from the sun and artificial sources to generate electricity from a transparent coating of organic photovoltaic solar cells applied to glass or plastics, creating a “photovoltaic” effect. Photovoltaics are best known as “solar panels” providing a method to generate electricity using solar cells to convert energy from the sun into a flow of electrons. Conventional PV power is generated by solar modules composed of interconnected mono- or poly-crystalline cells containing PV and electricity-conducting materials. These materials are usually opaque (i.e., not see-through) and only effectively generate electricity with sun light. The Company’s researchers have replaced these materials with a very thin layer of specially developed compounds that allow our SolarWindow™ technology to remain see-through or “transparent,” while generating electricity when exposed to either sun or artificial light.

Recent Accounting Pronouncements

In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a free-standing equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. Management is currently assessing the impact the adoption of ASU 2017-11 will have on the Company’s Consolidated Financial Statements.

In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting. The amendments in this Update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for public business entities for reporting periods for which financial statements have not yet been issued. Management is currently assessing the impact the adoption of ASU 2017-09 will have on the Company’s Consolidated Financial Statements.

In March 2016, the FASB issued ASU No. 2016-09, “Compensation-Stock Compensation: Improvements to Employee Share-Based Payment Accounting (Topic 718)”, which is intended to simplify several aspects of the accounting for share-based payment award transactions. The guidance is effective for our current fiscal year. The adoption of ASU 2016-09 did not have a material impact on the Consolidated Financial Statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842)”, which supersedes ASC Topic 840, Leases, and creates a new topic, ASC 842, Leases. The new guidance requires the recognition of lease assets and liabilities for operating leases with terms of more than 12 months. Presentation of leases within the consolidated statements of operations and consolidated statements of cash flows will be generally consistent with the current lease accounting guidance. The ASU is effective for reporting periods beginning after December 15, 2018, with early adoption permitted. The Company does not expect this accounting update to have a material effect on its Consolidated Financial Statements.

In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”). The standard requires that deferred tax assets and liabilities be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. ASU 2015-17 is effective for our current fiscal year. The adoption of ASU 2015-17 did not have a material impact on the Consolidated Financial Statements.

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”, to clarify the principles used to recognize revenue for all entities. In March 2016, the FASB issued ASU 2016-08 to further clarify the implementation guidance on principal versus agent considerations. The guidance is effective for annual and interim periods beginning after December 15, 2017. The Company does not expect this accounting update to have a material effect on its Consolidated Financial Statements.

The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion. The Company believes that none of the new standards will have a significant impact on its Consolidated Financial Statements.

Going Concern

The Company does not have any commercialized products, has not generated any revenue since inception and has sustained recurring losses and negative cash flows from operations since inception. Due to the “start-up” nature of our business, we expect to incur losses as we continue development of our products and technologies. As of May 31, 2018, the Company has incurred recurring operating losses since inception of $44,663,263. As of May 31, 2018, the Company had approximately $1,191,587 of cash on hand and current liabilities of $88,683. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which contemplates continuation of the Company as a going concern, which is dependent upon the Company’s ability to establish itself as a profitable business.

As of the date of filing of the Company’s most recent Form 10-K on November 22, 2017, based on management’s assessment, the Company had sufficient cash to meet its funding requirements for the next twelve months. However, currently, based upon the Company’s near term anticipated level of operations and expenditures, management believes that cash on hand should be sufficient to enable the Company to continue operations through January 2019 or approximately six months from the date of this quarterly report. In view of these conditions, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. These consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements.

The Company has negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The Company expects that it will need to continue to raise substantial additional capital to accomplish its business plan over the next several years, in line with previous expectations. The Company will seek additional funding through private equity or convertible debt. If adequate funds are not available on reasonable terms, or at all, it would result in a material adverse effect on the Company’s business, operating results, financial condition and prospects. In particular, the Company may be required to delay; reduce the scope of or terminate its research and development programs; sell rights to its SolarWindow™ technology and/or MotionPower™ technology, or other technologies or products based upon these technologies; or license the rights to these technologies or products on terms that are less favorable to the Company than might otherwise be available.

XML

Debt (Tables)

9 Months Ended

May 31, 2018

Debt

Outstanding debt

	Issue	Maturity			Debt					Interest
	Date	Date	Principal		Discount			Balance		Payable
As of May 31, 2018:
March 2015 Loan as amended	3/4/2015	12/31/2019	$	600,000	$	-		$	600,000	$	166,510
2013 Note as amended	10/7/2013	12/31/2019		3,000,000		(789,340	)		2,210,660		1,225,320
			$	3,600,000	$	(789,340	)	$	2,810,660	$	1,391,830
As of August 31, 2017:
March 2015 Loan as amended	3/4/2015	12/31/2017	$	600,000	$	-		$	600,000	$	113,465
2013 Note as amended	10/7/2013	12/31/2017		3,000,000		(413,377	)		2,586,623		932,912
			$	3,600,000	$	(413,377	)	$	3,186,623	$	1,046,377

XML

Common Stock and Warrants (Tables)

9 Months Ended

May 31, 2018

Common Stock And Warrants Tables

Warrants outstanding and exercisable

	Shares of Common Stock Issuable from Warrants Outstanding as of				Weighted
	May 31,		August 31,		Average
Description	2018		2017		Exercise Price		Expiration
Series M		246,000		246,000	$	2.34	December 31, 2022
Series N		767,000		767,000	$	3.38	December 31, 2022
Series O		-		618,000	$	3.10	October 31, 2017
Series P		213,500		309,000	$	3.70	December 31, 2022
Series Q		-		937,500	$	3.20	December 31, 2022
Series R		468,750		937,500	$	4.00	December 31, 2022
Series S-A		300,000		300,000	$	2.53	December 31, 2022
Series S		821,600		-	$	3.42	September 29, 2022
Total		2,816,850		4,115,000

XML

Stock Options (Tables)

9 Months Ended

May 31, 2018

Stock Options Tables

Fair value of each option award

	Nine Months Ended May 31,
	2018			2017
Expected dividend yield		–			–
Expected stock price volatility	83.43% – 83.55		%		81	%
Risk-free interest rate	2.27% - 2.33		%		2.03	%
Expected term (in years)		7.67			7.67
Exercise price	$4.87 - $5.35			$	3.28
Weighted-average grant date fair-value	$3.76 - $5.64			$	2.48

Stock option activity

	Number of Shares Subject to Option Grants	Weighted Average Exercise Price ($)	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value ($)
Outstanding at August 31, 2016	720,001	3.06
Grants	1,535,000	2.71
Exercises	(130,000)	2.62
Outstanding at August 31, 2017	2,125,001	2.84
Grants	1,263,000	5.25
Forfeitures and cancellations	(1,805,000)	2.74
Exercises	(291,667)	3.32
Outstanding at May 31, 2018	1,291,334	5.22	9.33 years	45,550
Exercisable at May 31, 2018	263,334	5.02	8.44 years	35,150

Share-based compensation cost

	Three Months Ended				Nine Months Ended
	May 31,				May 31,
	2018		2017		2018		2017
Stock Compensation Expense:
SG&A	$	215,695	$	26,667	$	796,371	$	102,589
R&PD		251,529		11,695		545,307		68,935
Total	$	467,224	$	38,362	$	1,341,678	$	171,524

Stock options outstanding and exercisable

	Stock Options Outstanding			Stock Options Exercisable
Range of Exercise Prices	Number of Shares Subject to Outstanding Options	Weighted Average Contractual Life (years)	Weighted Average Exercise Price	Number of Shares Subject To Options Exercise	Weighted Average Remaining Contractual Life (Years)	Weighted Average Exercise Price
3.28	7,500	8.46	3.28	7,500	8.46	3.28
3.46	35,000	7.60	3.46	25,000	7.60	3.46
4.87	207,500	9.48	4.87	92,500	9.48	4.87
5.35	1,008,000	9.59	5.35	105,000	9.59	5.35
5.94	33,334	2.57	5.94	33,334	2.57	5.94
Total	1,291,334	9.33	$5.22	263,334	8.44	$5.02

XML

Net Loss Per Share (Tables)

9 Months Ended

May 31, 2018

Net Loss Per Share Tables

Computation of basic and diluted net loss per share

	Three Months Ended May 31,						Nine Months Ended May 31,
	2018			2017			2018			2017
Basic and Diluted EPS Computation
Numerator:
Loss available to common stockholders'	$	(1,444,896	)	$	(1,202,337	)	$	(5,633,511	)	$	(4,211,138	)
Denominator:
Weighted average number of common shares outstanding		36,270,592			33,810,348			35,924,340			30,347,594
Basic and diluted EPS	$	(0.04	)	$	(0.04	)	$	(0.16	)	$	(0.14	)
The shares listed below were not included in the computation of diluted losses
per share because to do so would have been antidilutive for the periods presented:
Stock options		1,291,334			625,001			1,291,334			625,001
Warrants		2,816,850			3,944,000			2,816,850			3,944,000
Convertible debt		3,084,175			2,820,966			3,084,175			2,820,966
Warrants issuable upon conversion of debt (See "NOTE 2 - Debt" above)		3,084,175			2,820,966			3,084,175			2,820,966
Total shares not included in the computation of diluted losses per share		10,276,534			10,210,933			10,276,534			10,210,933

XML

Basis of Presentation, Organization, Recent Accounting Pronouncements and Going Concern (Details Narrative) - USD ($)	9 Months Ended
	May 31, 2018	Aug. 31, 2017	May 31, 2017	Aug. 31, 2016
Organization And Going Concern Details Narrative
State of incorporation	State of Nevada
Date of incorporation	May 05, 1998
Retained deficit	$ (44,663,263)	$ (39,029,752)
Cash and cash equivalents	1,191,587	670,853	$ 270,875	$ 2,509,215
Total current liabilities	$ 88,683	$ 230,184

XML

Debt (Details) - USD ($)	9 Months Ended	12 Months Ended
	May 31, 2018	Aug. 31, 2017
Principal	$ 3,600,000	$ 3,600,000
Debt Discount	(789,340)	(413,377)
Outstanding debt balances	2,810,660	3,186,623
Interest Payable	$ 1,391,830	$ 1,046,377
March 2015 Loan as amended [Member]
Issue Date	Mar. 04, 2015	Mar. 04, 2015
Maturity Date	Dec. 31, 2019	Dec. 31, 2017
Principal	$ 600,000	$ 600,000
Debt Discount
Outstanding debt balances	600,000	600,000
Interest Payable	$ 166,510	$ 113,465
2013 Note as amended [Member]
Issue Date	Oct. 07, 2013	Oct. 07, 2013
Maturity Date	Dec. 31, 2019	Dec. 31, 2017
Principal	$ 3,000,000	$ 3,000,000
Debt Discount	(789,340)	(413,377)
Outstanding debt balances	2,210,660	2,586,623
Interest Payable	$ 1,225,320	$ 932,912

XML

Debt (Details Narrative) - USD ($)

3 Months Ended

9 Months Ended

Nov. 03, 2017

Nov. 03, 2017

Mar. 04, 2015

Oct. 07, 2013

May 31, 2018

May 31, 2017

May 31, 2018

May 31, 2017

Aug. 31, 2017

Accretion of debt discount

$ (125,422)

$ (311,727)

$ (698,302)

$ (999,718)

Interest expense

128,706

79,162

345,453

231,626

Debt discount

789,340

789,340

$ 413,377

Bridge Loan One [Member]

Cash receved

$ 600,000

Interest rate

7.00%

Accretion of debt discount

0

0

0

74,702

Interest expense

$ 19,763

12,156

$ 53,045

35,462

Default rate

15.00%

Convertible Promissory Note [Member]

Cash receved

$ 3,000,000

Interest rate

7.00%

Debt instrument, terms of conversion feature

The Investor may elect to convert principal and accrued interest into units of the Company's equity securities, with each Unit consisting of (a) one share of common stock; and (b) one Stock Purchase Warrant for the purchase of one share of common stock. The conversion price for each Unit is the lesser of (i) $1.37; or (ii) 70% of the 20 day average closing price of the Company's common stock prior to conversion, subject to a floor of $1.00 with the exercise price of each Warrant being equal to 60% of the 20 day average closing price of the Company's common stock prior to conversion. If issued, the Warrant included in the Units will be exercisable for a period of five years

Convertible Promissory Note [Member] | Warrant [Member]

Commom stock shares issuable upon conversion of debt

3,084,175

3,084,175

December 31 2022 Member | Series S warrants [Member]

Debt instrument maturity date

Jul. 24, 2022

Commom stock shares issuable upon conversion of debt

300,000

300,000

Debt discount

$ 20,100

$ 20,100

Debt instrument, extended maturity date

Dec. 31, 2022

December 31 2022 Member | Series R warrants [Member]

Debt instrument maturity date

Jun. 20, 2021

Commom stock shares issuable upon conversion of debt

468,750

468,750

468,750

468,750

Debt discount

$ 295,781

$ 295,781

Debt instrument, extended maturity date

Dec. 31, 2022

December 31 2022 Member | Series P warrants [Member]

Debt instrument maturity date

Apr. 30, 2018

Commom stock shares issuable upon conversion of debt

213,500

213,500

213,500

213,500

Debt discount

$ 348,219

$ 348,219

Debt instrument, extended maturity date

Dec. 31, 2022

December 31 2022 Member | Series N warrants [Member]

Debt instrument maturity date

Dec. 31, 2020

Commom stock shares issuable upon conversion of debt

767,000

767,000

767,000

767,000

Debt discount

$ 327,509

$ 327,509

Debt instrument, extended maturity date

Dec. 31, 2022

December 31 2022 Member | Series M warrants [Member]

Debt instrument maturity date

Dec. 31, 2020

Commom stock shares issuable upon conversion of debt

246,000

246,000

246,000

246,000

Debt discount

$ 82,656

$ 82,656

Debt instrument, extended maturity date

Dec. 31, 2022

2013 Loan Agreement Member

Accretion of debt discount

125,422

311,727

$ 698,302

925,016

Interest expense

$ 108,943

$ 67,006

292,408

$ 195,480

Remaining debt discount

$ 789,340

Third Amendment to 2013 Bridge Loan Agreement [Member]

Debt instrument maturity date

Dec. 31, 2022

Debt discount

$ 1,074,265

$ 1,074,265

Interest rate, increase

10.50%

Investor [Member] | 2013 Bridge Loan Agreement [Member]

Debt instrument maturity date

Dec. 31, 2019

Investor [Member] | Third Amendment to 2013 Bridge Loan Agreement [Member]

Debt instrument maturity date

Dec. 31, 2019

Debt discount

$ 1,074,265

$ 1,074,265

Interest rate, increase

10.50%

Investor [Member] | 2015 Bridge Loan Agreement [Member]

Debt instrument maturity date

Dec. 31, 2019

Interest rate, increase

10.50%

XML

Private Placements (Details Narrative) - September 2017 Private Placement [Member] - USD ($)

Sep. 11, 2017

Sep. 29, 2017

Self directed shares issued

821,600

821,600

Self directed shares issued, per share

$ 3.11

$ 3.11

Self directed shares issued, amount

$ 2,555,176

$ 2,555,176

Unit price, description

The unit price was based on a 15% discount to the average of the 30-day closing price (last day being Friday September 8, 2017) of the Company's common stock as reported on the OTCQB.

Description of units issued

Each unit consisted of one share of common stock and one Series S Stock Purchase Warrant to purchase one (1) share of common stock at an exercise price of $3.42 per share through September 29, 2022

Exercise price of series S stock

$ 3.42

Relative fair value of common stock

$ 1,540,000

Relative fair value of series S-A warrants

$ 1,015,000

Market price per share

$ 3.95

Estimated volatility rate

77.96%

Risk free interest rate

1.71%

Expected dividend rate

0.00%

Expected life

5 years

XML

Common Stock and Warrants (Details) - $ / shares	9 Months Ended
	May 31, 2018	Aug. 31, 2017	Aug. 31, 2016
Shares of Common Stock Issuable from Warrants	2,816,850	4,115,000
Weighted Average Exercise Price	$ 5.22	$ 2.84	$ 3.06
Series M warrants [Member]
Shares of Common Stock Issuable from Warrants	246,000	246,000
Weighted Average Exercise Price	$ 2.34	$ 2.34
Expiration	Dec. 31, 2022
Series N warrants [Member]
Shares of Common Stock Issuable from Warrants	767,000	767,000
Weighted Average Exercise Price	$ 3.38	$ 3.38
Expiration	Dec. 31, 2022
Series O warrants [Member]
Shares of Common Stock Issuable from Warrants		618,000
Weighted Average Exercise Price	$ 3.10	$ 3.10
Expiration	Oct. 31, 2017
Series P warrants [Member]
Shares of Common Stock Issuable from Warrants	213,500	309,000
Weighted Average Exercise Price	$ 3.70	$ 3.70
Expiration	Dec. 31, 2022
Series Q warrants [Member]
Shares of Common Stock Issuable from Warrants		937,500
Weighted Average Exercise Price	$ 3.20	$ 3.20
Expiration	Dec. 31, 2022
Series R warrants [Member]
Shares of Common Stock Issuable from Warrants	468,750	937,500
Weighted Average Exercise Price	$ 4.00	$ 4.00
Expiration	Dec. 31, 2022
Series S-A warrants [Member]
Shares of Common Stock Issuable from Warrants	300,000	300,000
Weighted Average Exercise Price	$ 2.53	$ 2.53
Expiration	Dec. 31, 2022
Series S warrants [Member]
Shares of Common Stock Issuable from Warrants	821,600
Weighted Average Exercise Price	$ 3.42	$ 3.42
Expiration	Sep. 29, 2022

XML

Common Stock and Warrants (Details Narrative) - USD ($)			1 Months Ended			2 Months Ended	9 Months Ended		12 Months Ended
	Jan. 04, 2018	Sep. 07, 2017	Dec. 28, 2017	Nov. 21, 2017	Sep. 29, 2017	Oct. 30, 2017	May 31, 2018	May 31, 2017	Aug. 31, 2017	Sep. 11, 2017
Common stock, par value							$ 0.001		$ 0.001
Common stock, shares authorized							300,000,000		300,000,000
Common stock, shares outstanding							36,292,656		34,329,691
Proceeds from exercise of warrants							$ 2,949,326
Stock purchase option exercised							291,667		130,000
Shares reserved for issuance under 2006 Plan							2,550,085
Total shares issued to directors				160,000
Exercise price of shares issued to directors				$ 4.87
Common stock, shares issued during period to each director				40,000					46,520
September 2017 Private Placement [Member]
Self directed shares issued					821,600					821,600
Self directed shares issued, per share					$ 3.11					$ 3.11
Self directed shares issued, amount					$ 2,555,176					$ 2,555,176
Exercise price of series S-A stock					$ 3.42
Maturity date					Sep. 29, 2022
Alastair Livesey [Member]
Exercise price of shares issued to directors				$ 4.87
Common stock, shares issued during period to each director				50,000
Stock issuance lock-in period, description				75% of the 210,000 issued shares are subject to a one-year lock-up
Stock Option [Member]
Common stock, shares issued during period to each director							146,162
Stock Option [Member] | Alastair Livesey [Member]
Common stock issued upon exercise of Convertible securities			19,067
Stock purchase option exercised			36,667
Stock Option [Member] | John Conklin [Member]
Common stock issued upon exercise of Convertible securities	34,013	46,097
Stock purchase option exercised	50,000	100,000
Three Other Individuals [Member] | September 7, 2017 through April 13, 2018 [Member] | Stock Option [Member]
Common stock issued upon exercise of Convertible securities							46,985
Stock purchase option exercised							105,000
Series P warrants [Member] | Holders [Member] | December 1, 2017 Through April 30, 2018 [Member]
Common stock issued upon exercise of Convertible securities							39,500
Proceeds from exercise of warrants							$ 146,150
Exercise price of warrants							$ 3.70
Warrant exercised							39,500
Series R warrants [Member] | Third party [Member]
Common stock issued upon exercise of Convertible securities			285,823
Warrant exercised			468,750
Series Q warrants [Member] | Third party [Member]
Common stock issued upon exercise of Convertible securities		189,940
Warrant exercised		468,750
Series Q warrants [Member] | Investor [Member]
Common stock issued upon exercise of Convertible securities		189,940
Warrant exercised		468,750
Series O warrants [Member]
Common stock issued upon exercise of Convertible securities						80,000
Proceeds from exercise of warrants						$ 248,000
Exercise price of warrants						$ 3.10
Warrant exercised						80,000

XML

Stock Options (Details) - USD ($)	9 Months Ended		12 Months Ended
	May 31, 2018	May 31, 2017	Aug. 31, 2017
Expected dividend yield
Expected stock price volatility		81.00%
Risk-free interest rate		2.03%
Expected term (in years)	7 years 8 months 1 day	7 years 8 months 1 day
Exercise price	$ 5.25	$ 3.28	$ 2.71
Weighted-average grant date fair-value		$ 2.48
Minimum [Member]
Expected stock price volatility	83.43%
Risk-free interest rate	2.27%
Exercise price	$ 4.87
Weighted-average grant date fair-value	$ 3.76
Maximum [Member]
Expected stock price volatility	83.55%
Risk-free interest rate	2.33%
Exercise price	$ 5.35
Weighted-average grant date fair-value	$ 5.64

XML

Stock Options (Details 1) - USD ($)	9 Months Ended		12 Months Ended
	May 31, 2018	May 31, 2017	Aug. 31, 2017
Number of Options
Outstanding Beginning	2,125,001	720,001	720,001
Grants	1,263,000		1,535,000
Forfeitures and cancellations	(1,805,000)
Exercises	(291,667)		(130,000)
Outstanding Ending	1,291,334		2,125,001
Exercisable Ending	263,334
Weighted Average Exercise Price ($)
Weighted-average exercise price Beginning	$ 2.84	$ 3.06	$ 3.06
Grants	5.25	$ 3.28	2.71
Forfeitures and cancellations	2.74
Exercises	3.32		2.62
Weighted-average exercise price Ending	5.22		$ 2.84
Exercisable Ending	$ 5.02
Weighted Average Remaining Contractual Term
Outstanding Ending	9 years 3 months 29 days
Exercisable Ending	8 years 5 months 9 days
Aggregate Intrinsic Value ($)
Outstanding Ending	$ 45,550
Exercisable Ending	$ 35,150

XML

Stock Options (Details 2) - USD ($)	3 Months Ended		9 Months Ended
	May 31, 2018	May 31, 2017	May 31, 2018	May 31, 2017
Stock Compensation Expense:
SG&A	$ 215,695	$ 26,667	$ 796,371	$ 102,589
R&PD	251,529	11,695	545,307	68,935
Total	$ 467,224	$ 38,362	$ 1,341,678	$ 171,524

XML

Stock Options (Details 3) - $ / shares	9 Months Ended
	May 31, 2018	Aug. 31, 2017	Aug. 31, 2016
Number of shares subject to outstanding options	1,291,334	2,125,001	720,001
Weighted average contractural life (years)	9 years 3 months 29 days
Weighted-average exercise price	$ 5.22	$ 2.84	$ 3.06
Number of shares subject to options exercisable	263,334
Weighted average contractural life (years) of options exercisable	8 years 5 months 9 days
Weighted-average exercise price of options exercisable	$ 5.02
$5.94 Per Share [Member]
Number of shares subject to outstanding options	33,334
Weighted average contractural life (years)	2 years 6 months 25 days
Weighted-average exercise price	$ 5.94
Number of shares subject to options exercisable	33,334
Weighted average contractural life (years) of options exercisable	2 years 6 months 25 days
Weighted-average exercise price of options exercisable	$ 5.94
$5.35 Per Share [Member]
Number of shares subject to outstanding options	1,008,000
Weighted average contractural life (years)	9 years 7 months 2 days
Weighted-average exercise price	$ 5.35
Number of shares subject to options exercisable	105,000
Weighted average contractural life (years) of options exercisable	9 years 7 months 2 days
Weighted-average exercise price of options exercisable	$ 5.35
$4.87 Per Share [Member]
Number of shares subject to outstanding options	207,500
Weighted average contractural life (years)	9 years 5 months 23 days
Weighted-average exercise price	$ 4.87
Number of shares subject to options exercisable	92,500
Weighted average contractural life (years) of options exercisable	9 years 5 months 23 days
Weighted-average exercise price of options exercisable	$ 4.87
$3.46 Per Share [Member]
Number of shares subject to outstanding options	35,000
Weighted average contractural life (years)	7 years 7 months 6 days
Weighted-average exercise price	$ 3.46
Number of shares subject to options exercisable	25,000
Weighted average contractural life (years) of options exercisable	7 years 7 months 6 days
Weighted-average exercise price of options exercisable	$ 3.46
$3.28 Per Share [Member]
Number of shares subject to outstanding options	7,500
Weighted average contractural life (years)	8 years 5 months 16 days
Weighted-average exercise price	$ 3.28
Number of shares subject to options exercisable	7,500
Weighted average contractural life (years) of options exercisable	8 years 5 months 16 days
Weighted-average exercise price of options exercisable	$ 3.28

XML

Stock Options (Details Narrative) - USD ($)		1 Months Ended				9 Months Ended	12 Months Ended
	Jul. 07, 2017	Dec. 28, 2017	Dec. 27, 2017	Nov. 21, 2017	Nov. 15, 2016	May 31, 2018	Aug. 31, 2017
Stock option exercise, total						291,667	130,000
Closing stock option exercise price						$ 4.50
Stock option outstanding						42,500
Stock options granted	1,500,000
Stock options exercise price	$ 2.70					$ 4.50
Common stock, shares issued upon exercise of convertible securities				40,000			46,520
Aggregate intrinsic value of options						$ 32,500	$ 186,500
Share based compensation (Monthly)	$ 26,000
Common stock option vested	1,500,000
Stock option cancelled under consulting agreement						1,500,000
Grant date fair value per option	$ 1.84
Forfeitures						1,805,000
2006 Incentive Stock Option Plan [Member]
Stock option approved						5,000,000
Stock option available for grant shares						2,550,085
Stock option exercise						629,677
Stock option exercise, total						1,305,001
Maturity date						Feb. 07, 2021
Alastair Livesey [Member]
Stock options granted				255,000
Stock options exercise price				$ 4.87
Common stock, shares issued upon exercise of convertible securities				50,000
Two Employees [Member]
Stock options granted					35,000
Stock options exercise price					$ 3.28
Stock Option [Member]
Common stock, shares issued upon exercise of convertible securities						146,162
Aggregate intrinsic value of options						$ 1,045,135
Nonvested options forfeited, number of shares						5,000
Share based compensation expenses, reduced						$ 5,157
Cashless exercise options						291,667
Share based compensation expenses not yet recognized						$ 5,315,777
Share based compensation recognition period						3 years 9 months
Stock Option [Member] | Alastair Livesey [Member]
Stock option exercise, total		36,667
Employment Agreement [Member]
Stock options granted			1,008,000
Maturity date			Dec. 31, 2017
Vesting rate description			1/48th per month
Forfeitures			300,000
Exercise price			$ 5.35

XML

Net Loss Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	May 31, 2018	May 31, 2017	May 31, 2018	May 31, 2017	Aug. 31, 2017
Numerator:
Loss available to common stockholders'	$ (1,444,896)	$ (1,202,337)	$ (5,633,511)	$ (4,211,138)	$ (5,353,425)
Denominator:
Weighted average number of common shares outstanding	36,270,592	33,810,348	35,924,340	30,347,594
Basic and diluted EPS	$ (0.04)	$ (0.04)	$ (0.16)	$ (0.14)
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:
Stock options	1,291,334	625,001	1,291,334	625,001
Warrants	2,816,850	3,944,000	2,816,850	3,944,000
Convertible debt	3,084,175	2,820,966	3,084,175	2,820,966
Warrants issuable upon conversion of debt (See "NOTE 2 - Debt" above)	3,084,175	2,820,966	3,084,175	2,820,966
Total shares not included in the computation of diluted losses per share	10,276,534	10,210,933	10,276,534	10,210,933

XML

Related Party Transactions (Details Narrative) - USD ($)					3 Months Ended		9 Months Ended
	Nov. 03, 2017	Nov. 03, 2017	Aug. 07, 2017	Jul. 07, 2017	May 31, 2018	May 31, 2017	May 31, 2018	May 31, 2017	Aug. 31, 2017
Share based compensation (Monthly)				$ 26,000
Ownership percentage					10.00%		10.00%
Debt discount					$ 789,340		$ 789,340		$ 413,377
December 31 2022 Member | Series M warrants [Member]
Commom stock shares issuable upon exercise of warrants	246,000	246,000			246,000		246,000
Debt instrument extended maturity date							Dec. 31, 2020
Debt discount					$ 82,656		$ 82,656
December 31 2022 Member | Series N warrants [Member]
Commom stock shares issuable upon exercise of warrants	767,000	767,000			767,000		767,000
Debt instrument extended maturity date							Dec. 31, 2020
Debt discount					$ 327,509		$ 327,509
December 31 2022 Member | Series P warrants [Member]
Commom stock shares issuable upon exercise of warrants	213,500	213,500			213,500		213,500
Debt instrument extended maturity date							Apr. 30, 2018
Debt discount					$ 348,219		$ 348,219
December 31 2022 Member | Series R warrants [Member]
Commom stock shares issuable upon exercise of warrants	468,750	468,750			468,750		468,750
Debt instrument extended maturity date							Jun. 20, 2021
Debt discount					$ 295,781		$ 295,781
December 31 2022 Member | Series S-A warrants [Member]
Commom stock shares issuable upon exercise of warrants	300,000	300,000
Consulting Agreement [Member]
Related party expense					15,000	$ 15,000	45,000	$ 45,000
Mr. Bhogal [Member] | Consulting Agreement [Member]
Share based compensation (Monthly)			$ 5,000
Sierchio [Member]
Legal services					74,198	$ 101,138	220,032	$ 252,693
Satterlee [Member]
Owed amount included in accounts payable					$ 50,286		$ 50,286		$ 105,184
Third Amendment to 2013 Bridge Loan Agreement [Member]
Increase in interest rate		10.50%
Debt instrument extended maturity date		Dec. 31, 2022
Debt discount	$ 1,074,265	$ 1,074,265
Third Amendment to 2013 Bridge Loan Agreement [Member] | Investor [Member]
Terms of agreement	Third Amendment to the 2015 Bridge Loan Agreement, the rate of interest increased to 10.5% and the following warrants, held by the Investor, had their maturity date extended to December 31, 2022: a) Series M Warrant to purchase 246,000 shares; b) Series N Warrant to purchase 767,000 shares; c) Series P Warrant to purchase 213,500 shares; d) Series R Warrant to purchase 468,750; and e) Series S-A Warrant to purchase 300,000 shares
Increase in interest rate	10.50%
Debt instrument extended maturity date	Dec. 31, 2019
Debt discount	$ 1,074,265	$ 1,074,265